Translational feasibility of soluble nanobiotherapeutics with enhanced red blood cell functions
Introduction

General
The first reports on biotherapeutic artificial red blood cells (RBC) were published some time ago [1, 2] . Most people thought that artificial RBC was a simple matter that could be quickly developed for clinical use when needed. Thus, only the other areas of artificial cells were extensively developed around the world [3] [4] [5] . When AIDS came unexpectedly in the 1980s, there was no blood substitutes and many patients were infected with HIV contaminated donor blood. It was only then that intense research and development (R&D) on blood substitutes was belatedly carried out around the world. It was found out too late that blood substitute required the same long-term research as in any other medical research as for cancer and other diseases.
RBC
RBC have three major functions: (i) transport oxygen from the lung to the tissue, (ii) remove damaging oxygen radicals, and (iii) carry carbon dioxide (CO 2 ) from the tissue to the lung to be removed.
Hemoglobin-based oxygen carriers (HBOCs) with one RBC function, oxygen carrier
The initial urgency with HIV-contaminated donor RBC led researchers to concentrate on simple oxygen carriers without the other RBC functions. The most extensive clinical trials were based on polyhemoglobin (PolyHb) developed by Biopure on bovine PolyHb [6] , and Northfield on human PolyHb [7] . These use the basic principle of intermolecular crosslinking of hemoglobin [1] in the form of glutaraldehydecrosslinked hemoglobin first reported by Chang [2] . PolyHb has no blood group and can be pasteurized to inactivate HIV virus. After 20 years of intense R&D in USA, South Africa has approved it for routine use for anemia in surgery, because they still have HIV-contaminated blood problem [6] . In a 2009 US multicenter clinical trial of about 710 traffic accident patients, this has been given right in the ambulance without the need for blood group testing [7] . This can delay the need for blood transfusion for 12 h compared to 30 min for the control saline group. A 3% cardiac side effect compared to 0.6% in the control group raises discussion on risk/benefit in patients who would otherwise die if no RBC is available [7] . There have been considerable discussions regarding what causes the side effects [8] .
Soluble nanobiotherapeutic consisting of hemoglobin and antioxidant enzymes
This can be a soluble complex formed by crosslinking hemoglobin (Hb) with two RBC antioxidant enzymes, superoxide dismutase (SOD), and catalase (CAT) to form Poly-[Hb-SOD-CAT] [9] . Later, conjugated hemoglobin containing synthetic antioxidants (PNPH) [10] have also been prepared. Both of these can prevent nitric oxide depletion and also prevent ischemia-reperfusion injury. Other approaches discussed in details elsewhere [8] .
Soluble nanobiotherapeutic with enhancement of all three RBC functions
Do we need all three RBC functions in some conditions as in sustained severe hemorrhagic shock? Sim et al. [11] show in animal study that increase intracellular pCO 2 is related to increase fatality in severe hemorrhagic shock. They also show that intracellular pCO 2 is not the same as blood pCO 2. Tronstad et al. [12] show that increase intracellular pCO 2 is correlated with myocardial ischemia. We, therefore, add carbonic anhydrase (CA) to form a novel soluble nanobiotechnological complex Poly-[Hb-SOD-CAT-CA] with enhanced RBC functions for oxygen transport, oxygen radical removal, and CO 2 transport [13] .
Soluble nanobiotherapeutics: Poly-[Hb-SOD-CAT-CA]
We have recently crosslinked Hb, SOD, CAT, and CA into a soluble Poly-[Hb-SOD-CAT-CA] nanobiotechnological complex [13] . It not only has all three RBC functions, it can have enhancement of all three RBC functions by increasing the concentrations of RBC enzymes in the complex. Thus, we can have the same RBC enzyme activity or we can also enhance the enzyme activity of Poly-[Hb-SOD-CAT-CA] to two, four or six times that of RBC [14] .
Result in a 90 min severe hemorrhagic shock rat model
We studied this in rats with 90 min hemorrhagic shock at 30 mmHg mean arterial blood pressure (MAP) by removing two-third of blood volume [13] . Poly-[Hb-SOD-CAT-CA] with enhanced enzymes was significantly (P < .05) superior to blood in lowering of the elevated tissue pCO 2 ( Figure 1) ; recovery of the elevated ST ( Figure 2) ; lower troponin levels, lowering of elevated lactate, histology of the intestine, kidney, and heart [13] . PolySFHb is the crosslinking of stromafree hemoglobin that contains hemoglobin and RBC enzymes at the concentration normally present in the RBC. It shows the same effectiveness as RBC and superior to PolyHb (Figures 1 and 2 ) [13] .
Striking changes are observed in the histology of the intestine [13] . When reperfused with the animal's own blood, there is some detachment of the epithelium from the villi suggesting some tissue injuries but the gland architecture is still intact (Figure 3 ). The injury in the PolyHb group (Figure 4) shows injured villi and some damage to the glands but most of the glands still retain their structure. Poly-[Hb-SOD-CAT-CA] ( Figure 5 ) show intact mucosal structure with no obvious injuries.
What is the translational prospect for clinical use of this nanobiotherapeutic?
The following questions have to be resolved in order for us to see if this has any prospect for translation towards clinical applications. These include storage stability, pasteurization, costs and source of enzymes, and immunogenicity.
Storage stability
Poly-[Hb-SOD-CAT-CA] contains both Hb and enzymes, and enzymes are particularly sensitive to storage and heat. We solve this problem by freeze drying this into lyophilized powder that can be easily reconstituted into solution when needed [15] . Our recent detailed analysis shows that this extends the storage time of Poly-[Hb-SOD-CAT-CA] to 1 year Figure 1 . Effect of 90 min sustained hemorrhagic shock on intracellular pCO 2 and effects of different transfusion fluids. From Bian and Chang [13] with copyright permission. Figure 2 . Effects of different transfusion fluids on the recovery of ST elevation in 90 min sustained hemorrhagic shock rat model. From Bian and Chang [13] with copyright permission. at 4 C (compared to 42 days for RBC) and 40 days at room temperature (compared to 1 day for RBC) [15] . Poly-[Hb-SOD-CAT-CA] retains its oxygen carrying ability, P50 value, before and after long-term storage. After the freeze-dry process, the enzyme activities are 100 ± 2% for CA, 100 ± 2% for SOD, and 93 ± 3.5% for CAT.
Pasteurization
Unlike RBC or the solution form, the lyophilized form can be heat pasteurized at 70 C for 2 h to retain good enzyme activities of CA 97 ± 4%, SOD 100 ± 2.5%, and CAT 63.8 ± 4% [15] . Adding more CAT in crosslinking can maintain the same enzyme ratio after pasteurization. Further investigation is needed to study the potential use of pasteurization of the lyophilized preparation as an additional step to the preparative procedure that involves crosslinking with glutaraldehyde and ultrafiltration that can inactivate or remove infective agents. FDA has already approved the sterilization method used for PolyHb.
Costs of enzymes
Purified enzymes from commercial sources are extremely expensive. Our research resulted in a novel method to simultaneously extract SOD, CAT, and CA from the same sample of RBC [14] . This avoids the need for expensive commercial enzymes thus allowing this to be cost-effective for future large-scale production of a nanobiotechnological Poly-[Hb-SOD-CAT-CA] with enhancement of all three RBC functions. The best concentration of phosphate buffer was analyzed and established resulting in good recovery of CAT, SOD, and CA after extraction [14] . Different concentrations of the extracted enzymes can be used to enhance the activity of Poly-[Hb-SOD-CAT-CA] to two, four or six times that of RBC. When conditions only require Poly-[Hb-SOD-CAT-CA] with the same concentration of enzymes as RBC, then the content of RBC can be easily use without the need for enzyme extraction.
Source of hemoglobin and enzymes
This novel extraction method [14] will also allow us to extract the needed enzymes from any RBC source including discarded or contaminated donor RBC, post-stem cell extracted human placental RBC (cord RBC), bovine RBC or other RBC. Other possible sources include recombinant enzymes or bioengineered enzymes.
Effects of four weekly top loading including immunological effects
We are analyzing in details the effects of one-tenth blood volume top loading per week for 4 weeks. We follow the wellbeing, growth, biochemistry, histology, and also the important question of the immunological properties of this nanobiotechnological complex [16] . This work is ongoing with promising results. We are testing the immunological effects in rat by four weekly intravenously injection of one-tenth the total blood volume with the following three model system ( Figure 6 ) [16] :
BovineHb-BovineEnzymes as a test in human for
NonHumanHb-NonHumanEnzymes, For BovineHb-BovineEnzymes, there is a slight increase in antibody to bovine hemoglobin but not to the nanoencapsulated bovine enzymes. RatHb-RatEnzymes as test in human for HumanHb-HumanEnzymes, there is no increase in specific antibodies and there is no change in blood pressure before and after each of the four weekly injection. This shows that the procedure for the preparation did not result in changes in immunogenicity. For the RatHb-BovineEnzymes as a test for HumanHb-NonHumanEnzymes, there is no increase in specific antibodies and there is no change in blood pressure before and after each of the four weekly injection.
It would appear that the large amount of hemoglobin nanoencapsulate the small amount of enzymes and thus separate them from immunological reactions ( Figure 6 ). This suggests the possibility of using human hemoglobin together with nonhuman source of enzymes thereby saving the need to extract enzymes from human RBC. Human hemoglobin could come from discarded or contaminated donor RBC, post-stem cell extracted human placental RBC (cord RBC), and recombinant sources.
Summary
The results obtained up to now show promise towards potential translation for clinical use. However, much more detailed preclinical studies needs to be carried out. The final test will be the result of actual clinical trial in human.
Discussions
Comparison of different approaches
Progress in therapy is a stepwise process and we now have more experience and knowledge in this area. We can now tailor-make blood substitutes ranging from simple oxygen carriers to complex nanobiotherapeutics (Table 1) . However, if a condition only needs oxygen carriers then it would not be cost-effective to use a more complex nanobiotherapeutic. On the other hand, it would be folly not to use a more complex nanobiotherapeutic if indicated. Table 1 with enhanced RBC enzymes could prolong the safety window. 4. Heart attack and stroke can be caused by obstruction of arterial blood vessels. Unlike RBC particles, this nanobiotherapeutic being a solution can more easily perfuse through partially obstructed vessels to reach the heart and brain. Furthermore, its enhanced antioxidant enzymes (SOD and CAT) can effective remove oxygen radicals to prevent ischemia reperfusion injury to the reperfused tissues. 5. RBC have to be stored in refrigeration thus more difficult to transport and store in disaster, frontline, and remote areas. We show that lyophilized Poly-[Hb-SOD-CAT-CA] can be stored at room temperature for more than 40 days, compared to RBC of 1 day at room temperature. It can be stored in refrigeration at 4 C for more than 320 days as compared to RBC of 42 days.
Concluding remarks
In clinical medicine, there is no one single approach for all conditions. When the clinical condition only requires an oxygen carrier like PolyHb, then there is no need to use the more complex and more expensive Poly-[Hb-SOD-CAT-CA]. There are also conditions that may only require PolySFHb with the same enzyme functions as RBC. Other conditions may only require oxygen carrier with antioxidant functions. On the other hand, there are also conditions that may need Poly-[Hb-SOD-CAT-CA] with enhancement of all three RBC functions.
Translation to clinical use is very time consuming and we should learn from past experience not to wait until it is again too late. We should also analyze how research in animal studies can be applied to clinical use in patients. We also need to continue to look into the future since biological therapy undergoes rapid progress with many other future possibilities [8, 18] .
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Introduction
The blood cannot be pasteurized to inactivate potential infectious agents, and this had been a major problem during the human immunodeficiency virus (HIV) crisis in the year 1989. Other epidemics like Ebola may well come at any time. In addition, accidents, natural or man-made disasters, can result in severe injuries with extensive blood loss requiring urgent blood transfusion (Hess et al. 2011, Kim and Greenburg 2014) . However, much time can be lost because of the need to transport the injured to the hospital for blood group test before transfusion can be given. There is a safety window of delay for blood replacement in severe hemorrhagic shock (Hess et al. 2011 , Kim and Greenburg 2014 . Beyond this safety window, there can be problems related to ischemia-reperfusion injuries and irreversible shock. There are also problems related to the transport of donor blood, since it can only be stored for 1 day at room temperature and requires refrigeration at 4°C but even then only for about 42 days. Seven-micron-diameter red blood cells (RBCs) cannot easily perfuse into constricted microcirculation in severe hemorrhagic shock or partially obstructed vessels as in heart attack and stroke.
Polyhemoglobin (polyHb) is a water-soluble oxygen carrier based on the 1964 basic principle of nanobiotechno-logical assembly of Hb molecules . There was no initial interest in this until the 1989 crisis of HIV-contaminated blood. It took 20 years to develop this and other modified Hb oxygen carriers for clinical trials (Gould et al. 1995 , Klein 2000 , Chang 2005 , Burhop and Estep 2001 , Natanson et al. 2008 , Biro et al. 1995 . It was too late for many patients infected with HIV from contaminated donor blood. We need to learn from this lesson and be ready in case there is another unexpected epidemic like Ebola.
Large-scale U.S. clinical trials on bovine polyHb have been carried out in surgical patients . PolyHb has been approved for routine use in those countries, where these side effects are not as serious as the problem with insufficient supply of donor blood or HIV-contaminated donor blood (Kim and Greenburg 2014) . A U.S. randomized clinical trial ) in more than 700 prehospital ambulance patients for hemorrhagic shock shows that human polyHb can be given on the spot without the need for crossmatching. It can delay the need for blood transfusion for 12 h, whereas the control group that was given saline required blood transfusion in 30 min. There are nonfatal cardiac side effects in 3% of the polyHb group as compared with 0.6% in the control group.
Some other types of modified Hb have more severe side effects (Natanson et al. 2008 ). In conditions with endothelial dysfunction as in diabetes, there could be vasoconstriction (Yu et al. 2010) . In severe ischemia as in sustained severe hemorrhagic shock, myocardial ischemia or cerebral ischemia, there is the potential for ischemia-reperfusion injuries (Biro et al. 1995 .
It is important to resolve the adverse effect for more widespread use. Especially, this is because now there is again the potential of infectious agents that can lead to epidemics and contaminated donor blood in the same way as the disastrous HIV crisis. In addition, large-scale wars, terrorisms, and major accidents that require on the spot use of blood substitutes can also happen any time. We are wiser now and know that we cannot wait for the needs to come before carrying out serious research to resolve the side effects.
PolyHb is only an oxygen carrier but in addition to the transport of oxygen, RBCs have other two important functions, removal of oxygen radicals and transport of carbon dioxide (CO 2 ). We have shown earlier that polyHb needs antioxidant enzymes for the removal of oxygen radicals especially in ischemia-reperfusion (D' Agnillo and Chang 1998, Powanda and . This results in the removal of oxygen radicals and prevention of ischemiareperfusion injuries , Chang et al. 2004 , Nadithe and Bae 2011 . Superoxide dismutase (SOD) can also remove superoxide that would otherwise remove nitrate oxide to form peroxynitrate. This may help in preventing the removal of nitrate oxide that can lead to vasoconstriction in conditions with endothelial dysfunction (Yu et al. 2010 ). An extension of this is oxygen carrier with synthetic antioxidant enzymes (Ma and Hsia 2013). Do we need the third function of RBC-CO 2 transport -for the treatment of sustained severe hemorrhagic shock? The use of a novel intracellular pCO 2 microelectrode shows that in hemorrhagic shock, increase in intracellular pCO 2 is related to increase in mortality ). In addition, increase in tissue pCO 2 is related to the severity of myocardial ischemia ). Thus, we have added the CO 2 transport function of RBC by using carbonic anhydrase (CA) to form a soluble biotechnological complex of polyHb-SOD-catalase (CAT)-CA . With adjustments of the enzyme concentrations, this complex can have these RBC functions at enhanced levels.
Our earlier in vivo studies show that polyHb-SOD-CAT-CA could reduce the elevated tissue pCO2 level in a rat model of hemorrhagic shock within the 60-min safety window . We now present our detailed research data in a 90-min severe hemorrhagic shock rat model with 2/3 blood volume loss, which is beyond the 60-min safety window for rats.
Methods
Materials and methods
The following are the places of purchase and the materials used in this experiment: Sigma: potassium phosphate, toluene, sodium phosphate, 99% lysine monohydrochloride, 25% glutaraldehyde, Sephacryl S-300HR, 37% hydrochloric acid, CAT, SOD, CA, 30% Brij 35 solution, Drabkin's solution, and 3% (w/w) hydrogen peroxide; Fisher: 1.5  98 cm chromatography column and Millipore 100 kDa centrifugal filter; B. Braun Medical Inc.: lactated Ringer's solution; McGill University (MacDonald campus): fresh bovine blood; and Biopure Cooperation: ultrapure bovine Hb.
Preparation of SFHb
Stroma-free hemolysate (SFHb) is the content of RBCs with their membrane stroma removed. For preparing this, we used the method described in detail elsewhere . Fresh bovine blood with heparin was centrifuged at 4000 g for 60 min at 4°C to remove the plasma supernatant and upper layer of cell pellet. The RBCs were washed four times with sterile, ice-cold saline and then suspended in twice the volume of potassium phosphate (12.5 mM; pH, 7.4 ) for 30 min. Then 2 volumes of ice-cold reagent-grade toluene was used to remove stromal lipids. The sample was centrifuged at 16,000 g for 2 h at 4°C to remove cellular debris. The concentration of Hb was tested using Drabkin's solution. Our analysis shows that SFHb contains enzymes (SOD, CAT, and CA) that are normally present in RBCs (Table I) .
Preparation of polyHb-SOD-CAT-CA, polySFHb, polyHb, and polyHb-SOD-CAT
PolyHb-SOD-CAT-CA
PolyHb-SOD-CAT-CA was prepared by the method described in detail elsewhere . SOD, CAT, and CA were added to SFHb with a final concentration as shown in Table I . These were crosslinked by glutaraldehyde to construct polyHb-SOD-CAT-CA. First, 1.3M lysine was added at Nanobiotherapeutic for hemorrhagic shock 3 a molar ratio of 7:1 lysine/Hb before the crosslinking reaction. The reaction vessel was flushed with nitrogen gas and kept at 4°C at all times to prevent the formation of metHb. Twenty milliliters of the mixture was placed on a shaker at 4°C for 1 h at 140 rpm. Without stopping the shaker, 0.7 ml of 5% glutaraldehyde was slowly added to it at a molar ratio of 16:1 glutaraldehyde/Hb at a rate of 0.15-0.20 mL every 5-10 min. The reaction mixture was allowed to crosslink in the shaker for 24 h at 4°C. The crosslinking was stopped by adding 2.0M lysine at a molar ratio of 200:1 lysine/Hb.
PolySFHb
PolySFHb was prepared using the same method, but using the stroma-free content of RBCs (SFHb) with the normal blood cell concentration of SOD, CAT, and CA without the addition of more enzymes.
PolyHb
PolyHb was prepared by crosslinking ultrapure Hb that contained no RBC enzymes following the above-mentioned procedure but without adding enzymes. This represented the polyHb used in clinical trial.
PolyHb-SOD-CAT
PolyHb-SOD-CAT was prepared following the first procedure mentioned above, except that ultrapure Hb was used with the additional CAT and SOD to make up the final concentration as shown in Table I . This represented the sample with O2 transport and antioxidant functions but without CO 2 transport function.
Purification and concentration
Purification and concentration were carried out as follows: polyHb-SOD-CAT-CA, polySFHb, polyHb-SOD-CAT, and polyHb were each filtered using a sterile 0.45 uM filter and dialyzed against lactated Ringer's solution overnight at 4°C using a dialysis membrane. A Sephacryl S-300 column in a 4°C cabinet was used to remove only the fraction of free tetrameric Hb with molecular weight greater than 300 Ka. The samples were placed in a dialysis membrane on a bed of Sephacryl/Gel absorbent at 4°C and concentrated to a final Hb concentration of 10 g/dL.
The measurement of Hb concentration and SOD, CAT, and CA enzyme activities
Hb concentration
The Hb concentration was determined by colorimetry.
The samples were first reacted with Drabkin's solution (Sigma-Aldrich).
Then the concentration of the resulting cyanmetHb solution was measured by spectrophotometry at 540 nm.
SOD
SOD activity was determined by HT Superoxide Dismutase Assay Kit (R&D Systems), which followed the inhibition of nitroblue tetrazolium reduction using xanthine/xanthine oxidase as a superoxide generator.
CAT
CAT measurement was based on the rate of disappearance of H 2 O 2 as described elsewhere .
CA
For CA measurement, one Wilbur-Anderson (W-A) unit of CA activity was defined as the amount of enzyme that caused the pH of a 0.02 M Tris buffer to drop from 8.3 to 6.3. The reaction was initiated by the addition of substrate, and the time (T) needed for the pH of the reaction mixture to drop from 8.3 to 6.3 was recorded. A Fisher Accumet Basic pH Meter (Fisher Scientific, Pittsburgh, PA) with MI-407 (P) Needle pH Electrode (Microelectrodes Inc., Bedford, NH) was used to measure the change in pH caused by the hydration reaction of CO 2 catalyzed by CA. The control for the assay consisted of the same mixture without the test sample. The measurements in seconds were converted into W-A units according to the following formula:
The units were then plotted versus the Hb/CA concentration ).
Effects on tissue pCO 2 , mean arterial pressure, and electrocardiogram in a hemorrhagic shock rat model
The Animal Ethics Committee of McGill University has approved this experimental protocol. Sprague-Dawley rats, weighing 300  30 g, were randomly divided into 6 groups and each group contained 4 rats. Each of them was anesthetized with pentobarbital of 30 mg/g body weight. The animals were freely breathing and no ventilation support or oxygen was given during the protocol. This was to simulate hemorrhagic shock, where no ventilation support is available. Heparinized catheters were inserted into the right femoral vein and right femoral artery. Mean arterial pressure (MAP) was reduced by slowly withdrawing up to 2/3 volume of blood from the right femoral artery and maintained at 30 mmHg for 90 min. After this, each rat received one of 
Results
Effects on mean arterial blood pressure
In the groups with 2/3 volume of the blood removed, the MAP fell to 30 mmHg. In each group after 90 min at MAP of 30 mmHg, reinfusions of resuscitation fluids with different compositions (Table I ) had the effects that are shown in Figure 1 . The results of these individual groups were pooled together for comparison ( Figure 2 ). Here, a sham control group was also included. The sham control group showed no significant changes in MAP ( Figure 2 ). When transfused with 3 volumes of lactated Ringer's solution, the MAP increased transiently from 30 mmHg to 43.3  2.8 mmHg after 1 h (Figures 1 and 2 ). Reinfusion of the lost blood (with Hb of 15 g/dl) maintained the MAP at 91.3  3.6 mmHg.
When transfused with polyHb-SOD-CAT-CA (with Hb at 10 g/dL), the MAP was maintained at 87.5  5 mmHg when followed for 1 h after the infusion. PolySFHb, polyHb-SOD-CAT, and polyHb maintained the MAP at 85.0  2.5 mmHg, 86.0  4.6 mmHg, and 82.6  3.5 mmHg, respectively. However, there were other important criteria besides maintaining the MAP, which included changes in ST elevation, tissue pCO 2 , plasma lactate, and the integrity of the intestine and other organs.
the following resuscitation fluids intravenously through the femoral vein in 15 min: (The detailed composition of each fluid is shown in Table I ).
( MAP and electrocardiogram (ECG) were recorded using a Biopac Lab system (BIOPAC Systems Inc., Goleta, CA). Tissue pCO 2 was measured by placing a pCO 2 microelectrode (Lazar Research Labs, USA) on the surface of vastus medialis muscle at the incision site used for cannulation. MAP, tissue pCO 2 , and ECG were followed throughout the experiment and continued for 60 min after the completion of the above reinfusions. After this, the rats were given IP Nembutal to terminate these acute studies. The blood was collected at the end of the resuscitation and centrifuged at 5000 g for 10 min at 4°C to collect the plasma. The plasma was stored at  80°C before the assay. Cardiac troponin T (cTnT) was analyzed using a cTnT assay kit. Lactate assay kit was purchase from Biosource. Nanobiotherapeutic for hemorrhagic shock 5
Effects on elevated tissue pCO 2
The mean and standard deviation of each group were calculated and compared with the other groups. In the test groups with 2/3 volume of the blood removed, the baseline tissue pCO 2 of 54.7  2.5 mmHg increased steadily to 98  4. shock ST level, which is significantly better than the others (P  0.05). This is likely because polyHb-SOD-CAT-CA has all three RBC functions at an enhanced level, that is, oxygen and CO 2 transport plus antioxidant functions.
Effects on plasma lactate levels
In the case of plasma lactate level, after 90 min of sustained severe hemorrhagic shock it increased to 18  2.3 mM/L. PolyHb-SOD-CAT-CA reduced this to 6.9  0.3 mM/L in 60 min ( Figure 6 ). It is significantly more effective (P  0.05) than lactated Ringer's solution (12.
, and polyHb-SOD-CAT (7.6  0.3 mM/L).
Histology
Detailed results of the histological studies will be finalized and reported elsewhere. The most striking changes were in the intestine. Lactated Ringer's solution group showed (5) above, but more SOD, CAT, and CA enzymes were added to enhance the normal RBC enzyme activities. Reinfusion reduced the elevated tissue pCO 2 to 68.6  3 mmHg toward the normal levels after 60 min. This was significantly more effective than blood (p  0.05) that only reduced the tissue pCO 2 to 79.1  4.7 mmHg.
Effects on ST elevation
ST elevation in the ECG could be caused by ischemia, ischemiareperfusion injury, or abnormal tissue metabolism. The results of reinfusion of different fluids are shown in Figure 5 . Infusion of lactated Ringer's solution did not reduce the ST as it remained at 106  3.1% of the 90-min hemorrhagic shock ST level ( Figure 5 ). For polyHb, an oxygen carrier without any enzyme activities, the ST only recovered to 57.7  8.7% of the elevated level. Blood reduced the ST to 39.1  1.5%, while polySFHb to 38.3%  2.1%. PolyHb-SOD-CAT with its enhanced antioxidant enzymes reduced the ST to 27.8  5.6%. PolyHb-SOD-CAT-CA reinfusion reduced the ST to 21.7  6.7% of the hemorrhagic 
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form of polyHb-SOD-CAT-CA and not for the solution. After sterilization, the lyophilized form can be stored as such and can be easily reconstituted by dissolving in suitable solutions. Allowable storage time for RBC is about 1 day at room temperature and 42 days at 4C. The lyophilized form of polyHb-SOD-CAT-CA can retain sufficient enzyme activities when stored at room temperature for 320 days (Table III) .
Discussions
In ischemia-reperfusion study of hemorrhagic shock, stroke or myocardial infarction in animals, researchers use an ischemic period ranging from 30 min to 1 h with variable results. Our earlier studies on ischemia-reperfusion injuries in a rat model of combined hemorrhagic shock-brain ischemia show that a minimum of 60 min is needed . However, our more recent results show that 60 min is the safety window for the treatment of hemorrhagic shock in rats ). Thus, in order to avoid the pitfall of a very short ischemic period, and also to carry out a more stringent test, we are using 90 min for the present study.
We show in the present study that in severe hemorrhagic shock lasting for 90 min beyond the 60-min safety window, the novel nanobiotherapeutic polyHb-SOD-CAT-CA is superior to blood and other resuscitation fluids. It is more effective than RBC in reducing tissue pCO 2 . This is important since increased tissue pCO 2 has been related to increased mortality in hemorrhagic shock ) and severity of cardiac ischemia . It is also more effective than blood and the other resuscitation fluids for the recovery of ST and reducing the elevated plasma lactate level. It is also more effective in protecting the intestine in the reperfusion and resuscitation process. Being a solution, it can also better perfuse into the constricted microcirculation than RBC in hemorrhagic shock or partially obstructed vessels in heart attack and stroke. The enhanced antioxidant enzymes, CAT and SOD, can remove damaging oxygen radicals. SOD also removes superoxide and prevents it from reacting and removing nitric oxide to cause vasoconstriction. The lyophilized form can be heat sterilized to remove infectious agents like HIV or future infectious agents like ebola to avoid contaminated donor blood crisis in the future. It is not specific to blood groups and the lyophilized powder can be stored at room temperature for 320 days (Table III) . The lyophilized powder can be quickly reconstituted and dissolved for use. Since it does not need refrigeration or blood group damaged villi and glands. The polyHb group showed damaged villi and mild damage of glands. The blood reinfusion group showed damaged villi but intact glands. There were no signs of injury in the polySFHb, polyHb-SOD-CAT, and polyHb-SOD-CAT-CA groups. The histological results suggest that the presence of antioxidant enzymes, SOD and CAT, in the polySFHb, polyHb-SOD-CAT, and polyHb-SOD-CAT-CA could protect the intestine from ischemia-reperfusion injuries in severe 90-min hemorrhagic shock beyond the 60-min safety window. A summary of other findings can be found in Table II .
Stability at different temperatures including pasteurization
PolyHb can be heat sterilized and stored for 1 year even at room temperature Greenburg 2014, Gould et al. 1995) . However, polyHb-SOD-CAT-CA contains both Hb and enzymes, and enzymes are particularly sensitive to storage and heat. We thus carried out studies to analyze its heat sterilization stability and storage stability. The detailed methods and results will be finalized and reported elsewhere. A summary of the result is as follows (Table II) :
RBCs cannot be heat sterilized. On the other hand, after heat sterilization at 68°C for 2 h, lyophilized polyHb-SOD-CAT-CA retained good enzyme activities of SOD, 100  2.5%; CAT, 63.8  4%; and CA, 97  4%. More CAT can be added during the crosslinking process to maintain the same enzyme ratio after heat sterilization. It is important to note that heat sterilization at 68°C for 2 h is possible only for the lyophilized Figure 6 . Plasma lactate. PolyHb-SOD-CAT-CA reduced the plasma lactate level from 18  2.3 mM/L to 6.9  0.3 mM/L. It was significantly (p  0.05) more effective than lactated Ringer's solution (12.4 
, and polyHb-SOD-CAT (7.6  0.3 mM/L). testing, medics or ambulance can easily carry it and use it on the spot. This would avoid the life-threatening delays in emergency situations like mass disasters, war, and remote regions. However, polyHb-CAT-SOD-CA is just a potential nanobiotherapeutic with enhanced functions for specific applications. It is not meant to replace donor RBC with its much longer circulation time, which is essential for other long-term elective nonemergency uses. PolyHb-SOD-CAT-CA requires the use of enzymes that can be expensive if purchased in purified form from commercial sources. Thus, we have successfully extracted enzymes from RBC and used them in the preparation of polyHb-SOD-CAT ). We have more recently successfully extracted all three enzymes, SOD, CAT, and CA, for the preparation of polyHb-SOD-CAT-CA (Chen, Glynn and Chang, personal communication). This way, Hb and RBC enzymes can be extracted from outdated donor blood, placental cord blood (Li et al. 2006) , and from other sources, thus further utilizing RBC that would otherwise be discarded.
Our earlier study shows that polySFHb (contains enzymes at the same concentration as those in the RBCs) does not involve in immunological reactions and is not activated by anycomplement . If the higher amounts of enzymes in the new polyHb-CAT-SOD-CA resulted in immunological reaction, then we can use human enzymes extracted from outdated human donor RBC or human placenta cord RBC (Li et al. 2006) , or recombinant human enzymes.
Massive fluid and RBC replacement in severe injuries can lead to dilution of platelets and clotting factors resulting in bleeding (Hess et al. 2011 , Kim and Greenburg 2014 ). Our earlier study in rats also shows that the clotting time is markedly increased when more than 80% of blood is exchanged with polyHb (Wong and Chang 2009) . We have designed a soluble polyHb-fibrinogen complex that does not cause any increase in clotting time even when 98% of the blood has been exchanged with polyHb-fibrinogen (Wong and Chang 2007) . If needed, we can apply this to the polyHb-SOD-CAT-CA to obtain a nanobiotherapeutic that has not only enhanced RBC functions, but also a platelet-like function.
One theory regarding vasoconstriction in endothelial dysfunction is the removal of nitrate oxide by modified Hb (Yu et al. 2010 ). Superoxide may contribute to this problem since it removes nitric oxide to form peroxynitrate. The SOD component in polyHb-CAT-SOD-CA is effective in removing superoxide. This would prevent the removal of nitrate oxide to avoid vasoconstriction. In the unlikely event that polyHb-CAT-SOD-CA still causes vasoconstriction in endothelial dysfunction, we can use one of the available Hbs that has been modified to prevent vasoconstriction (Lui and Kluger 2011) . Other ways to prevent adverse vasoconstriction of modified Hb are also available (Yu et al. 2010, Jia and Alayash 2013) .
Stem cell culture for producing blood cells (Mazurier et al. 2011 ) has much promise for platelets and leucocytes that require only small volume. However, scaling up the liters of RBC needed for clinical use is still a major problem. When scale-up becomes practical, universal donor-group O-RBC can be produced. This will be very important for many important nonurgent uses of RBC. However, we shall still need polyHb-CAT-SOD-CA for emergency uses like sustained severe hemorrhagic shock for a number of reasons (Table IV) .
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Introduction
Serious research on blood substitutes only started after the HIV contaminated donor blood crisis in 1989. Nowadays, the worldwide demand and lack of supply of donor blood, as well as natural or man-made disasters or epidemics in some regions, resulted in an urgent need to develop blood substitutes [1] [2] [3] [4] [5] [6] [7] . The first generation of blood substitute is haemoglobin-based oxygen carrier (HBOC). One of these is in the form of polyhaemoglobin (polyHb) prepared by crosslinking Hb with diacid [8] or glutaraldehyde [9] . PolyHb has since been developed independently by many groups. For example, glutaraldehyde cross-linked bovine polyHb developed by Biopure has undergone extensive clinical trials [10] and already approved for routine clinical use in South Africa [6] . Another group from Northfield has developed glutaraldehyde crosslinked human polyHb and has carried out extensive clinical trials on ambulance hemorrhagic shock patients in the USA [11] . Their result shows that human polyHb can delay the need for blood transfusion by 12 h, while the saline control group requires blood transfusion within 1 h [11] . However, there are 3% non-fatal cardiac side-effects in the polyHb group compared with 0.6% in the control saline group. The investigators suggest that it has the potential for use in fatal hemorrhagic shock when donor blood is not available [11] . FDA did not approve this for clinical use, even though a number of investigators suggest that the risk/benefit ratios of polyHb have been shown in these emergency situations where donor blood is not available [7, [10] [11] [12] . For further improvement, the second generation blood substitutes have been developed in the form of poly-[haemoglobin-catalase-superoxide dismutase-carbonic anhydrase] or poly-[Hb-CAT-SOD] with antioxidant functions [13, 14] . This is important for ischemic condition including hemorrhagic shock to prevent ischaemia reperfusion injuries [15] by removing oxygen radicals during transfusion [16] . To enhance the antioxidant function, extra CAT and SOD enzymes are added to stroma-free haemoglobin (SFHb) for the development of poly-[Hb-SOD-CAT] which had been shown to prevent ischemia-reperfusion injury in a hemorrhagic shock-stroke rat model [14] . Hsia's group later extended this by using PEG-haemoglobin-antioxidant enzyme mimetics [17, 18] .
Researchers find that the mortality and the severity of myocardial ischemia in haemorrhagic shock are related to elevated intracellular pCO 2 [19] . Therefore, the third generation of blood substitute includes the addition of carbonic anhydrase (CA) to produce poly-[haemoglobin-catalase-superoxide dismutase-carbonic anhydrase] (poly-[Hb-CAT-SOD-CA]) [20] . This fulfills all three major functions of red blood cells as O 2 and CO 2 carrier and oxygen radical remover. Poly-[Hb-CAT-SOD-CA] with enhanced enzyme activities has been tested in a rat model of 90-min hemorrhagic shock with loss of 2/3 of blood volume. The result shows that poly-[Hb-CAT-SOD-CA] with enhanced enzyme activities is more effective than whole blood in lowering the elevated intracellular pCO 2 , improve cardiac recovery and avoid histological changes in liver, kidney, heart and intestine [21] .
Stroma-free haemoglobin (SFHb), is prepared from the content of red blood cells with the removal of the lipid membrane. SFHb contains Hb and all the red blood cell enzymes, including CAT, SOD and CA. To enhance the red blood cell enzymes, commercial CAT, SOD and CA are added for the preparation of poly-[Hb-CAT-SOD-CA] [20] [21] [22] [23] . For avoiding the high cost of commercial enzymes, a cost-effective novel enzyme extraction method has been established to obtain these three enzymes from SFHb simultaneously [24, 25] . This avoids the need for expensive commercial enzymes and allows the large-scale production of poly-[Hb-CAT-SOD-CA] in the future.
This paper studies the long-term safety and immune response to bovine sourced poly-[Hb-CAT-SOD-CA] (heterologous) in rats, using four-weekly top loading followed by a challenge with a larger volume (Figure 1 ).
The rats are divided into three groups and received one of the following samples: lactated ringer's solution (LR) as a control group, bovine polySFHb (Phe) and bovine poly-[Hb-CAT-SOD-CA] (PHE) with enhanced enzyme activity. Body weight, plasma biochemistry heart rate and mean blood pressure are tested during the four-weekly top-loading infusion period. Mean arterial pressures (MAP) are measured before and after each four-weekly top-loading. The immune study includes total IgG and IgM levels, Ouchterlony double diffusion, specific antibodies against bovine Hb, CAT, SOD and CA, and complement fragment 3a (C3a) activation test. After the four weekly top-loading, each rat is challenged with a larger 30% blood volume by exchange transfusion using one of control (LR), bovine Phe or bovine PHE. The MAP, total histamine and tryptase levels before and after transfusion are analyzed for possible anaphylactic reactions. There are no significant adverse response and no immunological reaction in rats against bovine sourced poly-[Hb-CAT-SOD-CA]. Life Science Inc (Woodland Hills, CA, USA). Enzyme-linked immunosorbent assay (ELISA) kits are purchased from different companies as indicated bellowed.
Methods and materials
Bovine stroma-free haemoglobin solution preparation
Stroma-free haemoglobin (SFHb) solution is the red blood cell content with the removal of a lipid membrane by an organic solvent. To separate red blood cells, the heparinized bovine whole blood is centrifuged at 4500 g at 4 C for 30 min. Remove the plasma layer carefully by vacuum suction using Pasteur pipet. Used ice-cold lactated Ringer's solution to ish the red blood cells thoroughly, then centrifuged (4500 g Â 30 min) again to remove the plasma residue. Repeated the ishing steps for two more times. After removing the supernatant, we collected the red blood cells, then added 2 volumes of cold lysis buffer (15 mM sodium phosphate, pH 7.4) to the red blood cells. Mixed the lysis buffer and the cells and incubated the mixture at 4 C for 30 min. Transferred the lyzed red blood cells to funnels and mixed with a half volume of cold toluene thoroughly. Placed the funnels in the fridge at 4 C overnight. Discarded the upper organic layer, then centrifuged the hemolysate at 16,000 g for 2 h. Bovine enzyme extraction and mix with bovine stroma-free haemoglobin solution SFHb contains haemoglobin and red blood cell enzymes including CAT, SOD and CA. The enzyme extracted had been established previously [24, 25] . 300 ml bovine SFHb (Hb concentration: 9g/dL) is placed in a beaker on ice. 60 ml potassium phosphate buffer (3 M, pH ¼ 7.4 ) is added to bovine SFHb. Stir the mixture with medium speed for 5 min on ice. Without stopping the stir, add drop-wise 120 ml ice-cold ethanol-chloroform solution with a speed of 1 drop/s. Continue stirring for 30 min with medium speed on the ice. Centrifuge solution 10 min at 5000 rpm at 4 C. Collect supernatant layer (usually around 20 ml) which contains SOD, CA, and CAT in >80% recovery and Hb % 0%. Transfer the supernatant to a new centrifugal tube, and centrifuge at 5000 rpm for 10 min at 4 C to precipitate the suspending denatured Hb. Transfer 12 ml supernatant to each Vivaspin 20 centrifugal filter with10 kDa cut-off and centrifuge at 6000 rpm at 4 C for 10 min. Add remaining supernatant to the same filters containing the enzyme solution and centrifuge at 6000 rpm for 15 min at 4 C. Ish the extracted enzyme solution in the centrifugal unit with 5 ml PBS (pH 7.4) in each filter to remove the remaining ethanol, mix the solution, and then centrifuge at 6000 rpm at 4 C for 15 min. Repeat the ishing steps two more times. To minimize the final volume of concentrated enzymes, ish the enzymes solution with 2 ml PBS (pH 7.4) in each filter and centrifuge at 6000 rpm at 4 C for 15 min. The final volume of concentrated enzymes should be approximately 300 ll in each filter.
Polymerization and purification
We crosslinked the SFHb with or without enzymes by glutaraldehyde to produce polySFHb or poly-[Hb-CAT-SOD-CA]. Mix 60 ml bovine SFHb (Hb concentration: 7 g/dL) with or without the concentrated enzymes that are prepared as described above. Add 1.5 ml 4 M NaCl, 1. Four Weekly small volumes (5% blood volume) top-loading infusions and measurement of body weight, biochemistry, antibodies, heart rate and mean arterial pressure
The Animal Ethics Committee of McGill University has approved this experimental protocol (protocol number: 2001-3816) . Sprague-Dawley rats, weighing 175 ± 20 g, are randomly divided into three groups and each group contains six rats. The rats are intravenously injected every week for four weeks in total. All the samples are filtrated through 0.45 lm filters before the Top-loading infusion. We placed the rat into a restrainer in Mouse and Rat Tail Cuff Blood Pressure (MRBP) system (IITC Life Science Inc., Woodland Hills, CA, USA) and warmed it up (32 C) for 15 min. We then measured the heart rate and MAP with the system. After the measurement, we injected the samples through tail vein. The following groups are injected once a week for 4 weeks in total:
a. Control LR: Lactated Ringer's solution, 1 ml; b. PHe: Bovine polySFHb (Hb: 7g/dL), 1 ml; c. PHE: Bovine poly-[Hb-CAT-SOD-CA] (Hb: 7 g/dL), 1 ml.
Each rat is injected with 1 ml of sample per week, which simulates infusing 250 ml per week for human for 4 weeks. Let the rat rest for 5 min in the system, then measured the MAP again. On the 5th week, rat plasma samples are collected from the rats through tail artery under anesthesia. Detail analytical procedures are described in the following part of plasma collection.
Larger challenge of 30% blood volume exchange transfusion after the above 4 weekly small volumes (5% blood volume) top-load At week 6, the rats grew up to 400 ± 25 g. We randomly selected four out of six rats after Top-loading infusion, then performed 30% blood volume exchange transfusion on the four rats with the same sample (LR, Phe, or PHE) that is used for the Top-loading infusion. The rat is anesthetized by consistent inhalation of isoflurane (12 ml/h, oxygen flow: 2 L/min) in a sealed chamber. When the rat is in the moderately deep plane of anesthesia, it is transferred to a ceramic plate with a heating pad for keeping the body temperature of the rat during the blood exchange. Electro-probes are used for monitoring the ECG by MP150 data acquisition and analysis system with Acknowledge software (BIOPAC Systems, Inc., Montreal, Canada). Isoflurane and oxygen are provided to a rat via inhalation mask throughout the whole procedure. Before the cannulation had been done, the isoflurane dose is 12 ml/h, oxygen flow: 2 L/min. A small incision about 1 cm is made on the skin at the left and the right femoral fossil region without cutting any tissue. Heparinized polyethylene catheters (PE10, Becton Dickinson and Company, Franklin Lakes, NJ, USA) are inserted into the left femoral artery and the right femoral artery and vein. The catheter in the left artery is connected to the MP150 system (BIOPAC Systems, Inc, Montreal, Canada) also for monitoring the MAP. The right femoral artery is cannulated for withdrawing the blood, while the right femoral vein is cannulated for infusion. After the catheters are placed in, isoflurane is adjusted to 6-9 ml/h, oxygen flow: 1-1.5 L/min). We allowed the MAP to be stabilized for 10 min after the adjustment of isoflurane/oxygen flow rate. After the stabilization, we withdraw 30% of the total blood volume (rat blood volume/rat body weight: 56 ml/kg) with a speed of 0.5 ml/min. Thus, we withdraw 7.5 ml of whole blood within 15 min. 1 ml of blood samples are collected for histamine and tryptase tests before infusion. We started to infuse the samples right after the bleeding within another 15 min. The samples for infusion are listed below. All the samples are filtrated through 0.45 lm filters before the infusion. After infusion, the MAP is monitored for 30 min to determine if there is an anaphylactic shock. Another 1 ml of blood samples are collected after the 30 min observation for histamine and tryptase analysis. At the end of the experiment, the catheters are removed, and arteries and vein are tied up with surgical polydioxanone suture (PDP304H, Ethicon) at the level of the femoral fossil to allow for anastomosis blood flow. 0.1 ml of lidocaine/bupivacaine is applied in the wound before closing the skin with surgical sutures (PDP304H, Ethicon). After the wounds are sutured, 0.4 ml of carprofen (10 mg/kg/day) is injected right away subcutaneously, and for the following two days thereafter. The rats are recovered from the 30% volume challenge and observed for one week.
Plasma collection
At week 5 and 7, after the rats are anesthetized by consistent inhalation of isoflurane (12 ml/hr, oxygen flow: 2 L/min). 2 ml blood is collected through a tail artery from each rat into lithium heparin tube. The whole blood samples are centrifuged at 1500 rpm, 4 C for 30 min. Plasma is collected and stored at À80 C until used.
Biochemistry test
The plasma biochemistry has been tested after four-week Top-loading infusion period and one-week recovery from blood exchange transfusion respectively to evaluate the safety of the samples to the rats with repeated injection. All the plasma samples are sent to the Animal Resources Centre at McGill University for the total panel test.
Quantification of total IgG and IgM levels in rats
To investigate the immune response to the samples, we tested the total IgG and IgM level in the rat plasma after four-week Top-loading infusion period and one week after 30% blood volume exchange transfusion respectively. The total IgG and total IgM are tested by the ELISA kits (Rat IgG total eBioscience 88-50490, Rat IgM eBioscience 88-50540). The testing methods are the same as instruction of the ELISA kits. Briefly, coat the ELISA plate with capture antibody (100 ll/well) in coating buffer, incubate overnight at 4 C. Then block the plate with blocking buffer (250 ll/well) at room temperature for 2 h or at 4 C overnight. After ishing the plates, adding 100 ll/well of standard samples with twofold serial dilution or test plasma samples onto the plates, incubate for 2 h at room temperature. Add the detection antibody (100 ll/well) into the plates. Finally, add 100 ll/well of substrate solution (TMB) and stopping solution and read the plates at 450 nm and 570 nm. The values of 570 nm are subtracted from those of 450 nm for data analysis.
Ouchterlony double diffusion
In order to detect the antibodies that may be produced to against the Phe or PHE, we did the double diffusion test on the rat plasma samples. The method of Ouchterlony double diffusion has been described elsewhere [26] . Agarose is dissolved in the PBS (pH7.2) to 1% by heating in a microwave. The agarose solution (10 ml) is poured to a depth of 5 mm into Petri dishes (diameter of 5 cm). The gels are allowed to cool down (for about 15 min) and form a gel at room temperature. Punch five holes (diameter of 7 mm) on each gel. Plasma samples from rats are loaded in the middle wells, while the other four wells are filled with 50 ll of the corresponding antigens (control LR, PHe and PHE) with serial concentrations: 0, 0.001 g/dL, 0.01 g/dL and 0.1 g/dL in the dilution of PBS (pH 7.4). The gel plates are then incubated at room temperature for 24 h.
Quantification of specific antibody against bovine haemoglobin, catalase, superoxide dismutase and carbonic anhydrase
To determine more specifically the antibodies against specific components in our poly-[Hb-CAT-SOD-CA], the ELISA tests for bovine Hb, CAT, SOD, and CA had been done on the rat plasma after four-week Top-loading infusion period and oneweek after 30% blood volume exchange transfusion. Antigen coatings are prepared by loading the solutions of pure enzymes of SOD (Sigma-Aldrich, St. Louis, MO, USA), CAT (Sigma-Aldrich, St. Louis, MO, USA), CA (Sigma-Aldrich, St. Louis, MO, USA) and Hb (Sigma-Aldrich, St. Louis, MO, USA) on the plates for fluorescent ELISA. Antigen solutions (10 lg/ml) are prepared in carbonate-bicarbonate buffer (pH 9.6). 0.2 ml of the above solution is pipetted into each well of the microtiter plate, followed by incubation (covered) at room temperature for 2 h. After incubation, the coating solution is removed, and ished three times by PBST. 0.2 ml Aqua block buffer (Abcam, Cambridge, UK) is loaded into each well and incubate at room temperature for 2 h.
To make the standard curve, monoclonal primary antibodies against bovine SOD (Abcam, Cambridge, UK), CAT (Abcam, Cambridge, UK), CA (Abcam, Cambridge, UK), and Hb (Santa Cruz Biotech, Dallas, TX, USA) are prepared in the buffer for Immunosorbent Assay (PBST and Aqua block buffer v/v 1:4). The primary antibodies started with the dilutions of 1:10,000 (SOD), 1:10,000 (CAT), and 1:100,000 (CA) and 1:50 (Hb). To test the antibody concentration in the plasma samples, the plasma samples are diluted by 1:3000 into dilution buffer. After the blocking procedure, plates are ished three times with PBST and 0.2 ml of the diluted monoclonal antibody is added to each well and Incubated at 4 C overnight. On the next day, plates are ished with PBST five times, and the secondary antibodies (Alexa Fluor V R z488, Abcam, Cambridge, UK) against the primary antibodies are prepared to be diluted 10,000 times with buffer for immunosorbent assay. 0.2 ml of this solution is added to each well, and incubated at room temperature for 2 h. After incubation, plates are also ished with PBST five times, and ensure there is no bubble remaining in each well. Absorbance is detected directly in a fluorescent microplate reader (Ex: 495 nm, Em: 519 nm).
Complement fragment 3a (C3a) activation
C3a levels in rat plasma samples are tested after four-week's Top-loading infusion period and one-week after 30% blood volume exchange transfusion respectively. As an important anaphylatoxin in the immune response [27] , it is produced in the complement activation cascade, via the cleavage of complement fragment 3 (C3) by C3 convertase. There are three pathways to activate the complement: classical pathway, alternative pathway and mannose binding lectin (MBL) pathway. They all participate in the activation of C3 followed by the formation of C3a. Complement activation has been shown to play an important role in many adverse reactions to modified haemoglobin [28] . With better sensitivity than C3, C3a is an indicator to monitor the complement activation [29] . The C3a level is determined by the ELISA kit (Cloud-Clone Corp. SEA387Ra, Katy, USA), based on the procedure of complement activation test [30] with slight changes. 0.1 ml of samples (control LR, PHe, or PHE) are mixed with 0.4 ml of corresponding plasma at 37 C at 60 rpm for 1 h. The reaction is quenched by transferring 0.4 ml of the plasma-sample mixture into 2 ml EDTA tubes to obtain the test samples. The method of ELISA test is the same as instruction of the kit. Add 100 ll/well of standard samples with two-fold serial dilution and 20-fold diluted test samples on the ELISA plates provided. 100 ll of biotin-antibody is then added to each well, followed by adding HRP-avidin (100 ll/well). Body weight changes of the rats during the four-week Top-loading infusion period. The body weight is measured in gram (g). Each figure shows a group of rats injected with corresponding sample (control LR, PHe, PHE). The body weight in rats injected with control (LR) are 158 ± 3.7 g, 227 ± 7 g, 288 ± 17 g, 348 ± 20 g. The body weight in rats injected with bovine PHe are 183 ± 9 g, 248 ± 15 g, 313 ± 9 g, 366 ± 25 g. The body weight in rats injected with bovine PHE are 198 ± 4 g, 257 ± 5 g, 318 ± 9 g, 367 ± 9 g. There are no significant differences from the control group.
Additional analysis for potential anaphylaxis with the 30% blood volume challenge
Quantification of histamine levels in rat plasma
Histamine is released by mast cells that are activated by IgE. The important inflammatory mediator, histamine, acts on the vessel dilation, smooth muscle constriction and inflammation, which leads to anaphylactic shock or other allergy symptoms such as rash and asthma [31] . Histamine levels are tested before and 30 min after the infusion of samples (control LR, PHe, PHE). The procedure is the same as the instruction of the ELISA kit (ab213975, Abcam, Cambridge, UK). Add 100 ll of assay buffer to the B 0 (0 ng/ml standard) wells and 150 ll of the same assay buffer to the NSB wells on the ELISA plate provided. Pipette 100 ll/well of standard histamine with two-fold serial dilution and plasma samples. Add 50 ll/well of histamine tracer except for the blank, and 50 ll/well of histamine antibody to all wells except for the NSB and blank. Incubate the plate at room temperature for 1 h. Use ishing solution ($400 ll/well) to ish the ELISA plate for three ishes in total. Add 200 ll/well of detection antibody into the wells except for the blank. Seal and incubate the plate for 30 min, followed by another three ishes. Applied 200 ll of TMB substrate and 50 ll of stopping solution to each well. Determined the optical density at 450 nm, subtracted by 570 nm value.
Quantification of tryptase levels in rat plasma
Tryptase is an enzyme released from mast cells when they are activated during the allergic responses. Hence, tryptase has been used as a diagnostic marker in anaphylaxis and mastocytosis [32] . Tryptase levels are tested before and 30 min after the infusion of samples (control LR, PHe, PHE). The procedure is the same as the instruction of the ELISA kit (E02M0256, BlueGene). Add 100 ll of standards or plasma samples to the appropriate wells. Add 100 ll of PBS (pH 7.0-7.2) in the blank control wells. Add 50 ll of the conjugate solution to each well except the blank control wells and mixing the wells thoroughly. Cover and incubate the plate for 1 h at 37 C. Ish the wells with ishing buffer for 5 times. Add 50 ll substrate A and 50 ll substrate B to each well including blank control well. Cover and incubate the plate for 10 min at 37 C in the dark place. Add 50 ll stop solution to all the wells and determine the optical density at 450 nm using microplate reader.
Statistics
Data are presented in a way of mean ± standard deviation (SD). The difference among the control groups (lactated Ringer's solution, LR) and bovine PHe and PHE groups are assessed by one-way ANOVA. To determine the relationship between the MAP and the week of injection, and the MAP changes during the 30 min observation period in the exchange transfusion, the correlation coefficients and its p values by two-sided are tested, with methods of Pearson, Kendall and Spearman. The confidence level is 95% in all tests. Figure 2 shows that the body weights of rats increase from 178 ± 20 g to 357 ± 30 g in four weeks. There are no significant differences from the control group of lactated Ringer.
Results
Effects on body weight
Effects on biochemistry
Biochemistry in rat plasma samples are tested after fourweekly 5% top-load and also one-week after 30% blood exchange transfusion (Table 1 ). For better interpretation and visualization of the results, some important indicators are selected for analysis in Figures 3 and 4 .
The indicators of kidney function, blood urea nitrogen (BUN) and creatinine, showed no significant difference between the control (LR) groups and the bovine sample groups. Albumin, albumin/globulin ratio, alanine transaminase (ALT), aspartate aminotransferase (AST) and bilirubin are the indicators of liver function. There are no significant difference among the control groups and bovine blood substitute groups. The level of creatine kinase (CK) also showed no significant difference between the control (LR) groups and the bovine sample groups in CK levels.
Ouchterlony double diffusion
Ouchterlony double diffusion test on the rat plasma samples are conducted to detect any antibodies produced against the Figure 3 . BUN urea, creatinine and CK levels. All data are in Table 1 . No significant statistical differences from the control groups. Figure 4 . Albumin, total bilirubin, ALT and AST levels. All data are in Table 1 . No significant statistical differences from the control groups.
bovine poly-[Hb-CAT-SOD-CA] after four-weekly top-loading infusions and one-week after exchange transfusion. Plasma samples are in the middle wells of the plates. Antigens with different concentrations are added to the peripheral wells. The concentrations of the antigens in the upper left, upper right, lower right and lower left wells are 0, 0.001 g/dL, 0.01 g/dL and 0.1 g/dL, respectively. These concentrations of antigens added to the wells gives a wide detectable range for the specific antibodies in plasma. If the plasma samples contain the antibodies that are against the injected antigens, an antibody-antigen precipitation would present between the two wells. Otherwise, no precipitation can appear. Figure 5 is the positive control of bovine serum albumin (BSA) showing BSA and anti-BSA antibody precipitation. Figure 6 for negative control, lactated Ringer, shows no precipitation line. Figure 6 shows no precipitation line with no antibodies against the bovine PolySFHb (PHe) or bovine poly-[Hb-CAT-SOD-CA] (PHE). After 30% blood volume exchange transfusion with control (LR), PHe or PHE, there is also no antigen-antibody precipitation (Figure 7 ).
Effects on total IgG and IgM levels in rats
Total IgG and IgM levels are tested after four-weekly 5% toploading and after 30% blood volume exchange to study the immune response to bovine poly-[Hb-CAT-SOD-CA] in rats (Figures 8 and 9 ). For total IgG tests (Figure 8) , there is no significant difference between the LR (control) group and the other two bovine samples groups. Total IgM levels ( Figure 9 ) after top-loading infusion with LR control group, PHe or PHE are 0.56 ± 0.33 mg/ml, 1.24 ± 0.60 mg/ml and 2.28 ± 0.87 mg/ ml; p values by one-way ANOVA is .002 (<.05). Total IgM levels after 30% blood volume exchange transfusion with LR control group, PHe or PHE are 0.57 ± 0.22 mg/ml, 1.79 ± 0.75 mg/ml and 2.11 ± 1.33 mg/ml; p values by one-way ANOVA is .14 (>.05). However, if we only compare the control group and PHe group by student's T-test, the p values is .035 (<.05); compare the control group and PHE by student's T-test, p value is .093 (>.05).
Effects on specific antibody against bovine haemoglobin, catalase, superoxide dismutase and carbonic anhydrase IgG and IgM changes could be due to many other reasons. The above double diffusion studies show that there is no Figure 6 . Ouchterlony double diffusion test on rats after 4 weekly 5% top-loading infusion with lactated ringer's solution as control, Bovine PHe or PHE (6 rats/ group) showing no antigen-antibody precipitations. Figure 7 . Ouchterlony double diffusion test on rats after 30% blood volume exchange transfusion with control (LR), PHe, or PHE (4 rats/group)) showing no antigen-antibody precipitations. antibody produced to the poly-[Hb-CAT-SOD-CA] complex itself. For more specific analysis, we carry out further studies on the potential antibody produced specifically against each component within bovine sourced poly-[Hb-CAT-SOD-CA], the excess of haemoglobin in the poly-[Hb-CAT-SOD-CA] complex nanoencapsulate, the more antigenic enzymes and can prevent them from theimmunological response ( Figure 10) .
Thus, specific antibodies against bovine Hb, CAT, SOD and CA are determined after: (1) four weekly top-loading infusions of LR, PHe and PHE; and (2) four weekly toploading infusions of LR, PHe and PHE followed by 30% blood volume exchange transfusion. As we can see from Figures 13  and 14 , after 5% top-loading infusion and followed by 30% exchange transfusion, there are no antibodies against bovine CAT and CA. There is also no significant difference in antibody levels against bovine Hb and SOD among control group (LR) and sample groups (PHe and PHE) (Figures 11  and 12) .
The values of anti-bovine Hb antibodies are 0.41 ± 0.09 mg/ml, 0.49 ± 0.13 mg/ml and 0.42 ± 0.08 mg/ml, respectively. The p values by one-way ANOVA is .83 (> .05). After 30% blood volume exchange, the antibodies against Hb in the group of control (LR), PHe and PHE are 0.44 ± 0.14 mg/ ml, 0.40 ± 0.10 mg/ml and 0.52 ± 0.11 mg/ml, respectively; p values by one-way ANOVA is .47 (> .05). The antibodies against SOD after four-weekly top-loading in control (LR), PHe and PHE are 1.92 ± 2.09 ng/ml, 1.30 ± 2.11 ng/ml and Figure 9 . Total IgM levels after four-weekly 5% blood volume top-loading infusions followed by 30% blood volume exchange transfusion. Total IgM levels after toploading infusion with LR control group, PHe or PHE are 0.56 ± 0.33 mg/ml, 1.24 ± 0.60 mg/ml and 2.28 ± 0.87 mg/ml; p values by one-way ANOVA is .002 (<.05). Total IgM levels after 30% blood volume exchange transfusion with LR control group, PHe or PHE are 0.57 ± 0.22 mg/ml, 1.79 ± 0.75 mg/ml and 2.11 ± 1.33 mg/ml; p values by one-way ANOVA is .14 (>.05). However, if we only compare the control group and PHe group by student's T-test, the p value is .035 (<.05); compare the control group and PHE by student's T-test, p value is .093 (>.05). Figure 8 . Total IgG levels after four-weekly 5% blood volume top-loading infusions followed by 30% blood volume exchange transfusion. After four-weekly injection-period, the total IgG levels in rat plasma against LR control group, PHe and PHE are 5.42 ± 2.36 mg/ml, 7.88 ± 3.13 mg/ml and 10.41 ± 7.80 mg/ml, respectively; p values by one-way ANOVA is .32 (>.05). After 30% blood volume exchange transfusion, the total IgG concentrations in LR control group, PHe and PHE group are 5.84 ± 1.86 mg/ml, 7.82 ± 3.27 mg/ml and 9.24 ± 5.80 mg/ml; p values by one-way ANOVA is .60 (>.05).
1.28 ± 2.57 ng/ml, respectively. p Values by one-way ANOVA is .48 (> .05). The antibodies against bovine SOD control (LR), PHe and PHE are 21.13 ± 7.57 ng/ml, 28.79 ± 15.07 ng/ml and 6.80 ± 7.79 ng/ml; p values by one-way ANOVA is .09 (> .05).
Effects on C3a activation
For more detailed evaluation of the immune response in terms of complement activation in rats, C3a levels after: (1) four-week 5% intravenous injections and (2) four-week t5% op-loading infusions followed by 30% blood volume exchange ( Figure 15) . In both cases, no significant difference can be seen in C3a levels between the LR control group and blood substitute groups. Figure 11 . The antibodies levels against SOD after 4-weekly Top-loading infusions in group of control (LR), PHe and PHE are 1.92 ± 2.09 ng/ml, 1.30 ± 2.11 ng/ml and 1.28 ± 2.57 ng/ml respectively. p Values by one-way ANOVA is .48 (> .05). The antibodies against bovine SOD in group of control (LR), PHe and PHE are 21.13 ± 7.57 ng/ml, 28.79 ± 15.07 ng/ml and 6.80 ± 7.79 ng/ml; p values by one-way ANOVA is .09 (> .05). Figure 12 . The concentration of antibodies against bovine Hb after four-weekly injection in group of control (LR), PHe and PHE are 0.41 ± 0.09 mg/ml, 0.49 ± 0.13 mg/ml and 0.42 ± 0.08 mg/ml, respectively. The p values by one-way ANOVA is .83 (> .05). After 30% blood volume exchange, the antibodies against Hb in group of control (LR), PHe and PHE are 0.44 ± 0.14 mg/ml, 0.40 ± 0.10 mg/ml and 0.52 ± 0.11 mg/ml, respectively; p values by one-way ANOVA is .47 (> .05).
Effects on mean arterial pressure during each 4-weekly intravenous injection
MAP is measured before and after each four-weekly 5% toploading each week. No significant difference in MAP between before and after injection can be seen (Figure 16 ). The correlation test is performed by r program, and the p values of all the correlation coefficients are > .05, thus we cannot reject the hypothesis that the correlation coefficients are 0.
Effect of 4 weekly 5% toploading followed by 30% blood volume exchange transfusion on mean arterial pressure
The MAP changes are monitored and recorded as shown in Figure 17 .
The first 10 min is the stabilization period. This is followed by 15 min of bleeding period with the removal of 30% of blood. After this, one of the samples (LR, PHe, PHE) is infused over 15 min. This is followed by 30 min of observation. There are no significant changes in MAP during the 30 min postinfusion period. Neither upward nor downward trend can be seen. The p values of all the correlation coefficients for the MAP in the 30 min observation period are > .05, thus we cannot reject the hypothesis that the correlation coefficients are 0. Therefore, no anaphylactic shock is observed after 30% blood volume exchange transfusion. In order for a more detailed test of anaphylactic changes, plasma histamine and tryptase are also followed (Figures 18 and 19 ).
Additional specific analysis on the potential anaphylactic effect as shown by histamine levels and tryptase levels before and after the larger challenge of 30% exchange transfusion The release of histamine by mast cells is responsible for anaphylactic reaction (Figure 18 ). However, histamine is unstable and measurement of plasma histamine is not accurate. . C3a activation test. After four-weekly injections, C3a levels in LR control group, PHe and PHE groups are 144.49 ± 4.39 ng/ml, 150.74 ± 6.38 ng/ml and 153.56 ± 9.90 ng/ml, respectively; p values by one-way ANOVA is .16 (>.05). After four-week top-loading infusions followed by 30% blood volume exchange, C3a levels in LR control group, PHe and PHE groups are 150.74 ± 1.60 ng/ml, 149.70 ± 2.77 ng/ml and 150.50 ± 3.18 ng/ml, respectively; p values by one-way ANOVA is .88 (>.05).
Tryptase is also released by the mast cell in an anaphylactic reaction. It is more stable and as a result, the measurement of plasma tryptase is more accurate.
To investigate more quantitatively whether there are any anaphylactic reactions after the larger challenge of 30% blood volume, histamine and tryptase levels are tested before and 30 min after infusion of samples (LR, PHe or PHE). There are no significant differences in histamine and tryptase analysis when comparing the LR control group and the bovine PolySFHb (PHe) and poly-[Hb-CAT-SOD-CA] (PHE) groups (Figure 19 ).
Histamine and tryptase levels are tested before and 30 min after 30% blood volume exchange transfusion of LR (control), PHe or PHE. The histamine levels in LR control group before and after infusion are 1058.62 ± 825.06 ng/ml and 695.47 ± 384.02 ng/ml. The histamine levels in PHe group before and after infusion are 730.37 ± 182.28 ng/ml and 992.30 ± 334.91 ng/ml. The histamine levels in PHE group before and after infusion are 1323.64 ± 598.83 ng/ml and 882.72 ± 156.77 ng/ml. The p values by one-way ANOVA among the three groups is .62 (>.05). The tryptase levels before infusion in LR, PHe and PHE groups are 4.04 ± 0.03 ng/ml, 4.01 ± 0.01 ng/ml and 4.04 ± 0.03 ng/ml; while after infusion, the values are 5.79 ± 0.06 ng/ml for the LR control group, 5.73 ± 0.02 ng/ml for PHe, and 5.71 ± 0.05 ng/ml for PHE. By comparing the LR control groups and the blood substitutes groups, the p values by one-way ANOVA is .51 (>.05) before the infusion, and the p values of after infusion is .21 (>.05). Thus, there are no significant changes in the histamine or tryptase levels between the control group and the PHe and PHE groups.
Discussion
In the present paper, we study the long-term safety and immunological effects of heterologous poly-[Hb-CAT-SOD-CA] (PHE) in rats after (1) four weekly 5% blood volume top-loading and (2) four weekly 5% blood volume top-loading followed by 30% blood volume exchange transfusion.
The rats in both the control group and bovine groups grew by 60 ± 10 g/week; and no significant difference between LR control group and PHe, PHE. There are no significant differences in the biochemistry between the control LR group and the bovine sample groups. The MAP before and after each of the four-weekly 5% top-loading showed no significant changes; and there is no significant difference between the control group and PHe, PHE groups. These results suggest that there are no adverse effects in rats after four weekly intravenous injections.
The effect on the immunological response is also studied. Ouchterlony double diffusion test is first performed as a screening test to see if there are any antibodies produced against the PHe, PHE complexes. There is no precipitate on the plates showing the absence of antibodies. This is followed by another screening test on the total IgG and IgM and there are no significant changes detected in IgG ELISA test. However, the IgM concentrations after top-loading infusions with bovine PolyHb-CAT-SOD-CA groups are higher than that in the control group (p < .05). Since total IgG and IgM test are nonspecific and could be the result of other causes, we carried out the more specific analysis by quantification of specific antibodies to the specific bovine components in PHe and PHE (Hb, CAT, SOD and CA). Specific antibodies against bovine CAT and CA are not detected; and no significant difference can be seen in the antibodies against bovine Hb or SOD between the control (LR) group and Phe, PHE. Moreover, no C3a activation is detected.
In order to rule out the possibility of an anaphylactic reaction, we carried out the following study. Four weekly 5% blood volume top-loading infusions of LR, PHe and PHE is followed by 30% blood volume exchange transfusion. The MAPs before and after each of the four weekly 5% toploading showed no significant changes. There are also no significant Figure 19 . Histamine and tryptase levels tested before and 30 min after 30% blood volume exchange transfusion of LR (control), PHe or PHE. Plasma trptase analysis is more accurate than histamine as shown by the higher SD for histamine. The histamine levels: the p values by one-way ANOVA among the three groups is .62 (>.05). The tryptase levels: comparing the LR control groups and the PHe and PHE groups, the p values by one-way ANOVA is .51 (>.05) before infusion, and the p values of after infusion is .21 (>.05). Thus, there are no significant changes in the histamine or tryptase levels between the control group and the PHe and PHE groups. changes after the larger challenge of 30% blood exchange following the 4 weekly 5% top-loading. There are also no significant alterations in histamine and tryptase levels before and after the 5% top-loading and also the 30% challenge that followed this. When followed for one week, all the rats survive and in good health after the 30% volume exchange transfusion. Thus, no anaphylactic reactions or adverse immune response are observed. In summary, no adverse long-term safety problems and mortality happened after the four weekly 5% volume topload followed by the 30% volume challenge. This study shows the potential to use bovine PolyHb-CAT-SOD-CA with enhanced red blood cell enzymes for transfusion. 
Full
Introduction
Polyhemoglobin (polyHb) is a fi rst-generation blood substitute prepared by the basic method of crosslinking the hemoglobin molecules with glutaraldehyde . Th is basic principle was later developed independently by two U.S. groups and tested in clinical trials , Kim and Greenburg 2014 . Bovine polyHb has been approved for use in patients in South Africa and Russia (Kim and Greenburg 2014) . U.S. clinical trials on ambulance hemorrhagic shock patients have shown that human polyHb can be given on the spot without blood typing, and can delay the need for blood transfusion by 12 hours, while the saline control group requires blood transfusion within 1 hour . Th e percentage of non-fatal cardiac side-eff ects was 3%, compared with 0.6% in the control group. Th e investigators propose that it has potential for use in treating fatal hemorrhagic shock when donor blood is not available ). Th e normal red blood cell (RBC) has three main functions: delivery of oxygen to tissues and cells; removal of oxygen radicals; and transport of carbon dioxide from tissues to the lungs . Ischemia/reperfusion injuries may occur in severe hemorrhagic shock, due to the production of oxygen radicals during reperfusion with transfusion (D'Agnillo and . Th e original blood substitutes were prepared from a RBC-stroma-free hemolysate (SFHb) that contains all the red blood cell enzymes, namely superoxide dismutase (SOD), catalase (CAT), and carbonic anhydrase (CA) . In order to enhance the antioxidant enzyme activities, we have added higher concentrations of the enzymes SOD and CAT, to prepare PolyHb -SOD -CAT (D'Agnillo and Chang 1998). Th is has prevented ischemia/reperfusion in a murine model of hemorrhagic shock stroke . In hemorrhagic shock, the mortality and the severity of myocardial ischemia are related to the elevated intracellular pCO 2 . Th e increase of intracellular carbon dioxide level may lead to acidosis, malfunction of the central nervous system, and even death . Th e RBC enzyme CA is the most important component for the transport of CO 2 Gros 2000, Arthurs and . Th is fact led this laboratory to prepare an even more up-to-date nanobiotechnological complex of polySFHb -SOD -CAT -CA, with higher concentrations of all three enzymes than those normally present in RBCs (Bian et al. 2012, Bian and . Th is polySFHb -SOD -CAT -CA complex with enhanced RBC enzyme activities has been tested in a murine model of 90-min hemorrhagic shock with loss of 2/3rds of blood volume. Th e result shows that it is more eff ective than whole blood in lowering the elevated intracellular pCO 2 , preventing cardiac side-eff ects, and preventing ischemia/reperfusion injuries in the liver, intestine, and heart .
Stroma-free hemolysate (SFHb) consists of the RBC content with the membrane removed. Th is contains hemoglobin and RBC enzymes including CAT, SOD, and CA. SFHb containing these enzymes has been used to prepare the earlier blood substitutes . However, even RBCs with normal CAT, SOD, and CA enzyme activities are not suffi cient to prevent irreversible shock in serious sustained hemorrhagic shock Greenburg 2014, Bian and . We therefore successfully prepared the polySFHb -SOD -CAT -CA complex by crosslinking SFHb with additional CAT, SOD, and CA Chang 2012, Bian and . However, commercial CAT, SOD, and CA are too expensive to scale-up production towards potential clinical use. have extracted SOD and CAT from SFHb. Ethanol -chloroform was used to denature the hemoglobin, followed by acetone precipitation to purify and precipitate the SOD. CA can also be extracted by the method of ethanol -chloroform treatment and acetone precipitation (da Costa Ores et al. 2012 ). However, this method results in the inactivation of CAT. Th us CAT had to be precipitated separately by adding ammonium sulfate . Th e eff ect of buff er on the stability of proteins has been studied by Ugwu and Apte (2004) . Th ey have shown that a phosphate buff er at a pH of 7.4 promotes the conformational stability of enzymes. Th erefore, we use potassium phosphate buff er (PPB) to protect CAT during ethanol -chloroform treatment in the present study. Extracting individual enzymes from diff erent batches of SFHb is neither effi cient nor cost eff ective. In the present study, we have designed an optimal method for extracting all three enzymes simultaneously from the same sample of SFHb.
In this study, we have successfully established the method to extract CAT, SOD, and CA from blood and crosslink them with SFHb to prepare PolySFHb -SOD -CAT -CA. Th e use of diff erent concentrations of PPB for the extraction was analyzed in detail. As a result, we have been able to establish the optimal concentration of PPB for the extraction of CAT together with SOD and CA. When adding 3 M PPB to SFHb, CAT activity can be retained in the Hb-free supernatant after ethanol -chloroform treatment; SOD and CA can also be obtained simultaneously. Finally, the extracted enzymes would be purifi ed and concentrated, followed by crosslinking them with SFHb to generate polySFHb -SOD -CAT -CA. Our results show that our modifi ed ethanol -chloroform treatment can maintain CAT, SOD, and CA activities with high recovery yields. Th e method we have established is expected to cut down the costs of scale-up production compared with the costs incurred using commercial enzymes.
Materials and methods
Materials
Stroma-free hemoglobin (SFHb) was prepared from bovine blood purchased from the McDonald Campus Cattle Complex at McGill University (Sainte-Anne-de-Bellevue, Canada). Both the Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane, and the Biomax polyethersulfone ultrafi ltration disc with 300 kDa cut-off were purchased from Millipore. All other experimental and analytical reagents were purchased from Sigma.
Preparation of SFHb
Th e method was based on that of . Briefl y, fresh heparinized bovine blood was centrifuged at 4,500 g for 30 min at 4 ° C. Th e plasma supernatant containing white blood cells and platelets was aspirated carefully on ice, leaving the red blood cells (RBCs) . Th e RBCs were washed with 0.9 M sodium chloride three times. Th ey were then lysed by adding 2 times the volume of hypotonic sodium phosphate buff er (12.5 mM, pH 7.4) to 1 volume of RBCs. Th e solution was mixed by repeated inversion and swirling, then left standing for 30 min at 4 ° C. A volume of 0.5 ml of cold toluene was added to the mixture. After shaking vigorously, the supernatant was allowed to stand for 3 hours at 4 ° C. Th e upper layer of the mixture, which contained toluene, stromal lipid, and cellular debris was removed by aspiration. Th e toluene step was repeated one more time, and the remaining solution was centrifuged at 16 000 g for 2 hours at 4 ° C. Th e supernatant was then fi ltrated by a fi lter paper. Toluene was removed by vacuum. Th e stroma-free hemoglobin solution was mixed by stirring, and distributed into 15 ml centrifugal tubes and stored at Ϫ 80 ° C.
Quantitative determination of Hb concentration
Th e concentration of Hb was colorimetrically determined by allowing the samples to react with Drabkin ' s reagent (SigmaAldrich). After 12 μ l of sample was added to 3 ml of Drabkin ' s reagent in a cuvette, the solution was allowed to stand for 15 min at room temperature, avoiding light. Th e concentration of cyanmethemoglobin in the solution was measured by spectrophotometry at 540 nm.
Determination of CAT activity
Th e established method has been described in the study paper by Zhu and Chang [21] . Th e SFHb and polySFHb samples were diluted at a ratio of 1:200 with PPB (50 mM, pH 7.0) to a total volume of 5 ml; while the SFHb mixed with extracted enzymes and polySFHb -SOD -CAT -CA samples was diluted at a ratio of 1:1000. Th e H 2 O 2 solution was prepared by adding 40.6 μ l of 30% H 2 O 2 solution to 9 ml of PPB (50 mM, pH 7.0). A UV spectrophotometer at 240 nm was used to measure the rate of elimination of H 2 O 2 within 15 seconds. For the blank, 1 ml of diluted sample and 0.5 ml of buff er were mixed. Th en, 1 ml of diluted sample mixed with 0.5 ml of H 2 O 2 solution was applied, to determine the CAT activity in the sample.
Determination of SOD activity
Th e SOD activity assay measures the decrease of cytochrome c by superoxide, observed using a UV spectrophotometer at 550 nm, within 50 seconds [11] . Th e SFHb and polySFHb samples were diluted 20-fold with PPB (0.1 M, pH 7.4), while the SFHb mixed with extracted enzymes and polySFHb -SOD -CAT -CA samples were diluted 100-fold. Th e reaction buff er prepared consists of potassium phosphate (50 mM, pH 7.8), EDTA (10 -4 M), xanthine (5 ϫ 10 -5 M), cytochrome Extraction of superoxide dismutase, catalase, and carbonic anhydrase from stroma-free red blood cell hemolysate 159 c (10 -5 M) , and catalase (500 U/ml). Xanthine oxidase was diluted with 0.154 M NaCl to 6 U/ml. Th e mixture of 1.45 ml of buff er and 25 μ l of diluted sample or buff er was applied as blank, and 25 μ l of xanthine oxidase (6 U/ml) was then added to initiate the reaction.
Determination of CA activity
Th e procedure for CA measurement was based on the method established by Bian in 2012 [17] . Tris buff er (20 mM, pH 8.3) and diluted samples were prepared, as above. Th e substrate of the reaction was prepared by bubbling CO 2 through distilled water. Th en, 10 μ l of diluted sample or the same amount of buff er as control was added into 3 ml of Tris buff er, while monitoring pH changes. To start the test, 2 ml of saturated CO 2 solution was added. Th e time needed for the pH of the mixture to drop from 8.3 to 6.3 was recorded.
Molecular weight distribution
A Sephacryl-300 HR column at a fl ow rate of 130 ml/hour was used for the analysis of molecular weight distribution. Th e column was equilibrated with 0.9% NaCl buff er. After 200 μ l of sample with Hb at a concentration of 9 g/dL was loaded into the column, 0.9% NaCl buff er was used to elute the sample. Th e molecular weight distribution was recorded by a 280 nm UV detector at a velocity of 5 mm/min.
Results
Eff ects of Potassium Phosphate Buff er Concentrations on Enzyme Extraction
For the study, we followed the procedure of enzyme extraction from hemolysate, as described in the next section, except that we used diff erent concentrations of PPB (pH 7.4): SFHb 3ml 1.
ϩ 4M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 2.
ϩ 3M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 3.
ϩ 2M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 4.
ϩ 1M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 5.
ϩ 0.1M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 6. ϩ 0.05M PPB 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 7.
ϩ water 0.6ml ϩ ethanol -chloroform 1.2ml SFHb 3ml 8.
ϩ ethanol -chloroform 1ml Table I summarizes the results obtained. Th e enzyme activity in the SFHb was considered as 100%. For CAT, there was little or no enzyme recovered at the lower phosphate buff er concentrations. Increase in the concentration of phosphate ions resulted in increased recovery of CAT, with the highest yield at 3M PPB. Th e reasons for the more than 100% apparent recovery of CAT activity will be explained in the Discussion. Th e recovery yields of SOD and CA were both around 70 -100%, compared with the activity recovered in SFHb. Th e concentration of phosphate buff er had no eff ect on the recovery yields of SOD and CA.
Based on these results, we used 3M for the fi nal procedure of enzyme extraction, as described in the next section.
Final method established for the extraction and concentration of enzymes from stroma-free hemolysate
A volume of 20 ml of SFHb is added to a beaker on ice, followed by 4 ml of 3M PPB (pH 7.4) , to obtain a fi nal concentration of 9 g/dL SFHb. Th e mixture is then stirred using a magnetic stirrer at medium speed for 5 mins, on ice. Next, 8 ml of cold ethanol -chloroform solution is added dropwise at a speed of 1 drop/sec, and then stirred for 30 min at medium speed on ice. Th e solution is centrifuged for10mins at 5000 rpm at 4 ° C. Th e supernatant layer (usually around 20 ml) is collected, which contains the recovered SOD, CA, and CAT, with little or no Hb. Th e supernatant is transferred to a new centrifugal tube, and centrifuged at 5000 rpm for 10 mins at 4 ° C to remove any remaining precipitated Hb. Next, 12 ml of the supernatant is transferred to the Amicon Ultra-15 Centrifugal 10 kDa fi lter unit and centrifuged for 10 min at 6000 rpm at 4 ° C. Th e remaining 8 -10 ml of supernatant is then added to the same fi lter unit containing the enzyme solution, and centrifuged at 6000 rpm for 15 mins at 4 ° C. Th e ethanol remaining in the extracted enzyme solution is washed out by adding 5 ml of 0.2M Na • PO 4 buff er (pH 7.4) to the centrifugal unit, mixing the solution, and then centrifuging at 6000 rpm at 4 ° C for 15 min. Th e washing steps are repeated two more times. Finally, to minimize the fi nal volume of concentrated enzymes, the enzyme solution is washed with 2 ml of Na • PO 4 buff er (pH 7.4) and centrifuged at 6000 rpm at 4 ° C for 15 mins. Th e fi nal volume of concentrated enzymes should be approximately 300 μ l.
Final method established for the preparation of PolySFHb -SOD -CAT -CA using extracted enzymes
A volume of 4 ml of 9 g/dl SFHb is added to diff erent amounts of the concentrated enzymes, prepared as described above. Th en 102 μ l of 4M NaCl is added to the solution and shaken at 160 rpm at 4 ° C for 5 mins. Frozen glutaraldehyde (0.5M) is thawed on an ice-water mixture using ultrasonication for 30 -40 mins. Th e glutaraldehyde must be mixed evenly before use. Without stopping the shaker, 162.3 μ l of glutaraldehyde is added dropwise in 4 equal aliquots at intervals of 15 mins, and shaken at 160 rpm for 24 hrs at 4 ° C. Next, 641.4 μ l of 2M lysine (200:1 lysine: protein molar ratio) is added in 2 equal aliquots over 10 mins and shaken at 160 rpm at 4 ° C for 1 hour, to quench. Th e solution is centrifuged at 8000 rpm at 4 ° C for 1 hour to remove any precipitate.
Th e polySFHb was prepared following the same procedure as for the preparation of polySFHb -SOD -CAT -CA, but products polySFHb -SOD -CAT -CA or polySFHb, most of the molecules were in the Ͼ 669 KDa range ( Figure 1A ). For SFHb, most of the molecules were in the 64KD hemoglobin range ( Figure 1B ).
Determination of Enzyme Activities and Recovery of Yield
Th e CAT, SOD, and CA activities were measured for the following samples before and after crosslinking: SFHb, and SFHb with concentrated enzymes added at 2x, 4x and 6x the original SFHb enzyme concentrations. After purifi cation of the polymerized molecules with the 300 KDa ultrafi ltration disc, the enzyme activities of the complexes were measured (Figures 2 -4 ). CAT activity in SFHb was found to be 53234 Ϯ 2945 U/g Hb. After crosslinking into polySFHb, the catalase activity was 20124 Ϯ 1053 U/g Hb). SFHb plus diff erent amounts of concentrated extracted enzymes before crosslinking and after crosslinking also showed good recovery of CAT activities ( Figure 2 ). For example, the CAT activity for SFHb with 2x extracted SOD, CAT, and CA was 153046 Ϯ 2207 U/g Hb before crosslinking, and 93034 Ϯ 3537 U/g Hb after crosslinking. With 4x extracted SOD, CAT, and CA, the activity was 160320 Ϯ 2205 U/g Hb) before crosslinking, and 135909 Ϯ 3918 U/g Hb after crosslinking. With 6x extracted SOD, CAT, and CA, the activity was 326989 Ϯ 7385 U/g Hb) before crosslinking, and 273919 Ϯ 7379 U/g Hb after crosslinking.
SOD activity in SFHb was found to be 1642 Ϯ 48 U/ml. After crosslinking into polySFHb, the SOD activity was 1114 Ϯ 33 U/ml (Figure 3 ). SFHb plus diff erent amounts of concentrated extracted enzymes before crosslinking and after crosslinking also showed good recovery of SOD activities (Figure 4 ). For example, the SOD activity for SFHb with 2x extracted SOD, CAT, and CA was 3567 Ϯ 100 U/g Hb) before crosslinking, and 2846 Ϯ 68 U/g Hb after crosslinking. For 4x extracted SOD, CAT and CA, the activity was 4526 Ϯ 65 U/g Hb) before crosslinking and 4149 Ϯ 69 U/g Hb after crosslinking. For 6x extracted SOD, CAT, and CA, the activity was without adding the extracted enzymes. Th e supernatant of the crosslinked sample was around 4 -5 ml. Th e sample was purifi ed using a 300 KDa ultrafi ltration disc with positive air pressure. After purifi cation, the Hb concentrations of the crosslinked samples were tested and adjusted to 9g/dL with 0.1M PPB (pH 7.4).
Molecular Weight Distribution
Th e molecular weight distributions of polySFHb -SOD -CAT -CA, polySFHb, and SFHb were analyzed with Sephacryl S-300 gel column chromatography. A volume of 200 μ l of supernatant was loaded on the column. In the polymerized Extraction of superoxide dismutase, catalase, and carbonic anhydrase from stroma-free red blood cell hemolysate 161 9124 Ϯ 338 U/ml before crosslinking and 6712 Ϯ 181 U/ml after crosslinking. CA activity in SFHb was 16725 Ϯ 411 U/g Hb. After crosslinking into polySFHb, the CA activity was 18638 Ϯ 711 U/g Hb ( Figure 4 ). SFHb plus diff erent amounts of concentrated extracted enzymes before crosslinking and after crosslinking also showed good recovery of CA activities (Figure 4 ). For example, the CA activity for SFHb with 2x extracted SOD, CAT, and CA was 25722 Ϯ 758 U/g Hb) before crosslinking and 24547 Ϯ 574 U/g Hb after crosslinking. For 4x extracted SOD, CAT, and CA, the activity was 62776 Ϯ 680 U/g Hb before crosslinking and 54707 Ϯ 400 U/g Hb after crosslinking. For 6x extracted SOD, CAT, and CA, the activity was 140243 Ϯ 2911 U/g Hb before crosslinking and 101869 Ϯ 4248 U/g Hb after crosslinking.
Discussion and conclusion
PPB at a pH of 7.4 can prevent CAT from aggregation after ethanol -chloroform treatment. It is likely that the ion strength and pH value of the buff er contribute to the aggregation of hemoglobin and the stability of the three enzymes. Th e molecular weights (MW) of hemoglobin, CAT, SOD, and CA are 68 KDa, 250 KDa, 32.5 KDa, and 29 KDa respectively. Th e isoelectric points (pI) of hemoglobin, CAT, SOD, and CA are 6.8, 5.4, 4.95, and 5.9 respectively. As we can see, only the pI of hemoglobin is close to the pH of the solution at 7.4; thus hemoglobin tends to aggregate when adding organic solvents that have reduced dielectric strength (Crowell et al. 2013) . In spite of its low pI value, CAT also aggregates after ethanol -chloroform treatment, possibly due to its large size and the ion pairing eff ect. However, when increasing the fi nal concentration of phosphate ions from 20.3 mM to 257.8 mM, the improvement in CAT recovery yield can be observed (Table I) . Th e phosphate buff er may be able to protect CAT because a large amount of ions migrate to the charged surface residues to generate a solvent layer, preventing the aggregation of CAT; the pI of hemoglobin is close to the pH of solution, therefore hemoglobin cannot attract enough ions to form a hydration shield. Interestingly, the phosphate buff er was reported to destabilize the hemoglobin by binding to the 2,3-bisphosphoglycerate (2, site (Ugwu and Apte 2004) .Th erefore, the phosphate buff er at a pH of 7.4 can protect CAT and simultaneously promote hemoglobin precipitation.
Why is it that compared with the original enzyme activities assayed in SFHb, the apparent CAT activities increase in the extracted enzyme solution after ethanol -chloroform treatment? Th ere are a number of possible explanations. Firstly, hemoglobin has peroxidase-like activity (Paco et al. 2009 ). We have done the following test on the eff ect of hemoglobin on CAT activity. When CAT is added to the SFHb, the total CAT activity of the mixture is lower than the summation of CAT activities in the extracted enzymes and the SFHb (Figure 2 ). Th erefore, it is likely that hemoglobin may suppress the CAT as a competitive inhibitor. Secondly, ethanol has been found to increase the CAT activity (Magner and Klibanov 1995) . We compared the activity of pure CAT and CAT-ethanol mixture. Th e ethanol concentration in this test is equal to the concentration during the extraction procedure. Th e result shows that 12.5% ethanol can increase CAT activity by 1.4 times. Th irdly, hemoglobin can be converted to choleglobin by coupling with ascorbic acid in the presence of oxygen (Miller 1958) . Choleglobin formation can even increase when RBCs are hemolyzed (Foulkes and Lemberg 1949) . Th e hemoglobin -ascorbic acid complex is the intermediary substance in choleglobin formation and acts as a hydrogen peroxide donor (Miller 1958) . Th e assay of CAT is based on the measurement of H 2 O 2 left after the reaction of samples with H 2 O 2 solution.
In conclusion, we have devised a novel method to simultaneously extract all three enzymes, CAT, SOD, and CA, from RBC hemolysate (SFHb). When using bovine RBC, the unlimited and inexpensive source of bovine blood would be much less costly than commercial enzymes to scale-up the production of blood substitute. Earlier studies from this laboratory have shown that bovine PolySFHb containing the bovine RBC enzymes did not show immunological reactions when tested in rats . We shall investigate the eff ects of using higher concentrations of enzymes. If there is an immunological problem, we can also use our novel method for the extraction of human hemoglobin and enzymes from human placental RBCs (cord RBCs) for the preparation of polySFHb -SOD -CAT -CA.
Introduction
Blood substitute firstly draws the attentions of researchers after the HIV crisis. Nowadays, the blood scarcity is a worldwide problem due to the increasing demand and lack of supply as well as HIV in some regions of the world . The first generation blood substitute is based on the basic principle of polyhemoglobin (PolyHb) ). This has been developed independently by others and has undergone extensive clinical trials , Chang 2014 , Kim and Greenburg 2014 and Zhao et al. 2014 . It is already approved for routine clinical use in countries where HIV in donor blood is still a major problem. This includes South Africa and Russia , OPK Biotech LLC 2011 . However, in countries where HIV is no longer an urgent problem, PolyHb is still not yet in routine clinical use. Red blood cell (RBC) has three main functions: oxygen transport, antioxidant and CO 2 transport Gros 2000, Guyton 1991 ). The first generation of blood substitute like PolyHb is merely an oxygen carrier while the second generation blood substitute, polyhemoglobin-superoxide dismutase-catalase (Poly-[Hb-SOD-CAT]) (D'Agnillo and Chang 1998), is both an oxygen carrier and an antioxidant. This way, it functions well in preventing ischemia-reperfusion injuries (Chang 2014 . Other research groups have supported this finding (Hoffman 2003 , Mun et al. 2003 . However, this cannot transport CO 2 . CO 2 transport is one of the vital functions of RBC (Ristagno et al. 2006 . The importance of this function has been proved by recent studies. Thus, using a novel intracellular pCO 2 microelectrode, researchers show that tissue pCO 2 is not reflected by blood pCO 2 . Furthermore, tissue pCO 2 increases with severity of hemorrhagic shock and is correlated with mortality rates . Poly-[SFHb-SOD-CAT-CA] is a new type of blood substitute . The SFHb, SOD, CAT, CA were all cross-linked together to form a nano-sized soluble blood substitute. The in vitro analysis showed that the enrichment of enzymes before the crosslink highly improved the activities of SOD, CAT and CA in Poly-[SFHb-SOD-CAT-CA]. And an optimal Poly-[SFHb-SOD-CAT-CA] with the following addition of enzymes requires an Hb: SOD:CAT:CA ratio of 1 g:18,000:310,000:130,000 U. Besides, the main part of Hb and enzymes were contained in the samples larger than 100 kDa . The primary in vivo experiment showed that Poly-[SFHb-SOD-CAT-CA] could efficiently rescue the MAP and reduces the increased pCO 2 in the ischemia rat model after 90-min shock. And this new blood substitute performed better than whole blood in reducing elevated tissue pCO 2 as well as the recovery of elevated STelevation .
Since this new blood substitute contains abundant enzymes, the long-term stability of this polymer needs to be analyzed. When it is stored in the ambulance or in places without proper storage condition, the enzyme activities in different temperature should also be tested.
Lyophilization of PolyHb can markedly increase its storage stability (Keipert and Chang 1988, Zhao et al. 2014) . We, therefore, analyze the potential use of lyophilization to increase the stability of the enzyme components. The enzymes activities and other characters of the freeze-dried samples, including molecular distribution and P50 values were assessed before and after lyophilization as well as during the long-term storage.
Besides stability, we also use the in vitro screening test . For short, the complement activation of C3 to C3a of the plasma added with blood substitute was evaluated. Using saline and zymosan as control, the effects of Poly-[SFHb-SOD-CAT-CA] on complement activation of the plasma could be easily analyzed.
Methods
Stroma-free hemolysate preparation
Fresh bovine blood with heparin (anticoagulant) was centrifuged at 4000 g for 60 min at 4 C to remove the plasma supernatant and upper layer of the cell pellet. The RBCs were washed four times with sterile, ice-cold 0.9% NaCl and then suspended in twice the volume of potassium phosphate (12.5 mm, pH 7.4) for 30 min in order to lyse. Then, two volumes of ice-cold reagent-grade toluene were used to remove stromal lipid. The sample was centrifuged at 15,000 g for 2 h at 4 C to remove cellular debris.
Preparation of Poly-[SFHb-SOD-CAT-CA]
The enzymes, including SOD, CAT and CA were added to SFHb before crosslink to reach a final concentration of SOD (1050 U/ml SFHb), CAT (21,000 U/ml SFHb) and CA (1070 U/ml SFHb). The crosslinking reagent, glutaraldehyde, was used to crosslink Hb, SOD, CAT and CA together to form Poly-[SFHb-SOD-CAT-CA]. 1.3 M lysine was added at a molar ratio of 7:1 lysine/Hb before the cross-linking reaction. Trehalose was added at the ratio of 0.2 g/1 g Hb to prevent the formation of methemoglobin (MetHb). The mixture was placed on a shaker at 4 C for 1 h at 140 rpm. Five percent glutaraldehyde was added slowly at a molar ratio of 16:1 glutaraldehyde/Hb at a rate of 0.15-0.20 ml every 5-10 min. After 24 h, the addition of 2.0 M lysine at a molar ratio of 200:1 lysine/Hb is used to stop the reaction.
Measurements of SOD, CAT and CA activities
The enzyme activity testing methods have been presented before. For short, SOD activity was determined by inhibition of nitro blue tetrazolium reduction using xanthine-xanthine oxidase as a superoxide generator.
For the CAT activities, UV 240 nm spectrophotometric method was used to measure the rate of disappearance of H 2 O 2 and test samples were used as a blank to minimize hemoglobin interferences. The CA activity is measured by the pH change of 0.02 M Tris buffer. The reaction was initiated by the addition of substrate and the time (T) needed for the pH of the reaction mixture to drop from pH 8. C to obtain oxygen-hemoglobin dissociation curves.
Lyophilization procedure
The Poly-[SFHb-SOD-CAT-CA] and SFHb added trehalose at the ratio of 1 g Hb:0.8 g trehalose as the protective agent. And after frozen at À80 C overnight, the samples were freeze-dried by the freeze-dryer machine.
Storage stability analysis of solution and freeze-dry samples
Poly-[SFHb-SOD-CAT-CA] and free solution of SFHb, SOD, CA and CAT were prepared and then stored in different temperature for enzymes activity testing at day 0, 1, 2, 4, 8, 16, 32, 64, 128 . Lyophilized Poly-[SFHb-SOD-CAT-CA] and SFHb were stored at temperatures of À80 C, 4 C, 20 C, 37 C. The enzyme activities are tested before and after freeze-dry and also tested on days 10, 20, 40, 80, 160. The molecular weight of the samples was evaluated by Sephacryl-300 HR column. This column was equilibrated with 0.1 M Tris-HCl and 0.15 M NaCl (pH 7.4) elution buffer. The molecular weight distribution was recorded at 1 mm/min using a 280-nm UV detector.
Effect of pasteurization temperature on the stability of soluble and freeze-dry samples
The samples of Poly-[SFHb-SOD-CAT-CA] solution and freezedried samples were kept at 70 C for 1, 2 and 3 h and tested the SOD, CAT and CA enzymes activities separately. The molecular distribution of the freeze-dried samples after 3 h was also analyzed.
Effects on C3a complement activity
Rat plasma is obtained from Sprague-Dawley rats and transferred into 50 ml polypropylene heparinized tubes. The plasma is separated by centrifugation at 5500 g for 20 min at 2 C. The fresh plasma is transferred in 400 ul aliquots into 4 ml sterile polypropylene tubes. Four-hundred microliters of plasma is combined with 100 ul Ringer's lactate solution as negative control. Four hundred microliter of plasma is combined with 100 ul of zymosan (5 mg/ml) as positive control. Poly-[SFHb-SOD-CAT-CA] is the testing samples. The samples are incubated at 37 C at 60 rpm for 1 h in the Lab-Line Orbit
Environ Shaker (United States of America). The reaction is quenched by adding 0.4 ml of the samples to 1.6 ml sterile saline in 2 ml ethylenediaminetetraacetate (EDTA) sterile tubes. The complement C3a des Arg (human), EIA kit was purchased from Amersham, Canada. The testing method is the same as the instruction given in the kit except for two minor modifications. Centrifugation is carried out at 10,000 g for 20 min and the inside of the tubes are carefully blotted with Q-tips.
Results
Effects of lyophilization on enzyme activity
After the freeze-dry process, the enzyme activities of Poly-[SFHb-SOD-CAT-CA] was 93 ± 3.5% for CAT, 100 ± 2% for SOD and 100 ± 2% for CA (Table I) . ). This is followed by the results of more detailed analysis:
(1) CA activity: After 320 d of storage, the freeze-dried Poly-[SFHb-SOD-CAT-CA] stored at À80 C, 4 C, 25 C and 37 C contained 86 ± 3%, 85 ± 2%, 73 ± 2.5% and 55 ± 4% separately of their enzyme activities (Figure 1 ). After 128 d storage, Poly-[SFHb-SOD-CAT-CA] solution stored at À80 C, 4 C, 25 C, 37 C contained 69.3 ± 3%, 57 ± 1.5%, 42 ± 1.5%, 21 ± 4.5% of their enzyme activities. However, free enzymes stored at À80 C, 4 C, 25 C, 37 C dropped to 54 ± 6%, 44.3 ± 2.5%, 27.4 ± 4% and 8.2% ± 1% (Figure 1 ). samples retained 96 ± 3%, 87.5 ± 3% and 65 ± 1% of their original activities when stored at À80 C, 4 C and 25 C. The free enzyme solution retained 81 ± 6%, 77 ± 2% and 58 ± 2% when stored at À80 C, 4 C and 25 C. When kept at 37 C, there was an extensive loss of CAT activity after 128 d to 20 ± 4% even though this is better than the free uncrosslinked enzymes with only 2 ± 3% ( Figure 3 ). Ongoing study also show that Poly-[SFHb-SOD-CAT-CA] prepared with the new enzyme extraction method ) also has increased temperature stability.
Molecular distribution of Poly-[SFHb-SOD-CAT-CA] solution and freeze-dried samples
For the freeze-dried samples, results showed that freeze-dry could make the complex more stable. When freeze-dried samples were stored at 23 C, 4 C or À80 C, the molecular weight distribution of the samples did not change after 1 year (Table III) . Even samples kept in 37 C for 1 year were also more stable than the solution form with no free Hb (lower than 100kDa) detected (Table III) . For the soluble Poly-[SFHb-SOD-CAT-CA] samples, the percentage of the molecular distribution is respectively, 83% for molecular weight larger than 450 kDa; 17% for between 100 kDa and 450 kDa and not detectable for those less than 100 kDa. After 4 months storage at À80 C and 4 C, there was no significant changes in the molecular weight distribution. Storage at 25 C and 37 C for 4 months resulted in significant dissociation of molecular weight as shown in Table IV . At the pasteurization temperature of 70 C, the enzyme activity of SOD, CAT and CA was, respectively, 100 ± 3%, 67.4 ± 1% and 100 ± 5% after 1 h at 70 C, 100 ± 2.5%, 63.8 ± 4% and 97 ± 4% after 2 h 70 C and 100 ± 4%, 46.7 ± 5% and 94 ± 5% after 3 h 70 C (Table V) . After the pasteurization, the molecular weight distribution of the freeze-dried Poly-[SFHb-SOD-CAT-CA] did not change.
For the solution, after 30-min pasteurization, the enzyme activities remained are: SOD 83.4 ± 4%, CAT 28 ± 1% and CA 87.6 ± 4%. After 1 h at 70 C, SOD and CA still contain 81.5 ± 3%
and 77 ± 6%, while the CA dropped to zero. After 2 h, the enzyme activity of SOD, CAT and CA were 64 ± 7%, 0% and 62 ± 6%. After 3 h, the SOD, CAT and CA activities are 57.8 ± 10%, 0% and 50 ± 6%, respectively. The freeze-dry procedure improves the enzyme stability even at the pasteurization temperature of 70 C. On the other hand, when not freeze-dried the enzyme stability, especially for CAT, are not stable at the pasteurization temperature of 70 C.
Methemoglobin content
Trehalose was added to reduce the MetHb content of the Poly-[SFHb-SOD-CAT-CA] during the crosslinking process. The best ratio is 0.2 g/gHb. This resulted in the lowering of MetHb from 15% down to 8%. Trehalose is not toxic and can be removed efficiently by ultrafiltration. This protective agent is also added during the freeze-dry process to prevent the increase of MetHb.
Results showed that trehalose could efficiently reduce the MetHb content when added at the ratio of 0.8 g/gHb. Oxygen carrying ability of different samples before and after long-term storage The P50 value of Poly-[SFHb-SOD-CAT-CA] was 20.0 ± 0.74 mmHg. After storing in different temperature À80 C, 4 C, 25 C and 37 C for 3 months, the P50 value of soluble Poly-[SFHb-SOD-CAT-CA] were 21.19 ± 1.8, 21.31 ± 1.93, 21.88 ± 1.41, 22 .04 ± 0.55 mmHg, respectively. For the freeze-dried sample, the P50 values were 14.94 ± 0.38, 14.22 ± 1.4, 14 .57 ± 1.1, 13.32 ± 0.93 after 1 year storage (Table VI) .
Effects on C3a complement activation
C3a des Arg levels were measured in this study as an indication of activation of the complement pathway. C3a is a multifunctional, proinflammatory mediator and has the ability to mediate hypersensitivity, anaphylactic reactions and specific antibodyantigen responses. The conversion of C3 to C3a is triggered by either classical or alternate complement pathways. C3a des Arg, can be quantified by ELISA assay. Poly-[SFHb-SOD-CAT-CA] sample were either similar to or slightly lower than levels in the negative control which is Ringer's lactate with plasma. The positive control of zymosan with plasma did exhibit higher levels of C3a. These results suggest that Poly-[SFHb-SOD-CAT-CA] does not activate the complement pathway in rat plasma (Table VII) .
Immunological studies
Ongoing immunological studies show that there is no increase in immune response to Poly-[Hb-SOD-CAT-CA] even with six folds increase in enzyme contents.
Discussion
The allowable storage time for RBC is 42 d at 4 C and around 1 d at room temperature. The above result shows that the lyophilized form of Poly-[SFHb-SOD-CAT-CA] retains most of its enzyme activity after 320 d when stored at 4 C and also in room temperature. In the soluble form, it has a T1/2 of 198 d at 4 C and 51 d in room temperature. This means that the lyophilized form can be stored for a year in room temperature and reconstituted when needed. The soluble form with a T1/2 of 51 d at room temperature is comparable to RBC stored at 4 C in the refrigerator. Without the need for refrigeration, it would be much more convenient to this to be transported even in a backpack of the medics. Furthermore, the lyophilized form of Poly-[SFHb-SOD-CAT-CA], unlike RBC can withstand a heat pasteurization temperature of 70 C for 2 h. This is important to allow the preparation to be free of infective agents for use in patients.
The complement activation studies show that the crosslinking and lyophilizing procedure did not result in any problems related to complement activation. Further, ongoing detailed immunological studies in animals are ongoing. 0.5 h (65 C) 101 ± 4% 78 ± 5% 102 ± 4% 1 h (70 C) 100 ± 3% 67.4 ± 1% 100 ± 5% 2 h (70 C) 100 ± 2.5% 63.8 ± 4% 97 ± 4% 3 h (70 C) 100 ± 4% 46.7 ± 5% 94 ± 5% 
